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ABSTRACT 
Iterative in situ click chemistry (IISCC) is a robust general technology for development 
of high throughput, inexpensive protein detection agents. In IISCC, the target protein acts as a 
template and catalyst, and assembles its own ligand from modular blocks of peptides. This 
process of ligand discovery is iterated to add peptide arms to develop a multivalent ligand with 
increased affinity and selectivity. The peptide based protein capture agents (PCC) should ideally 
have the same degree of selectivity and specificity as a monoclonal antibody, along with 
improved chemical stability. We had previously reported developing a PCC agent against bovine 
carbonic anhydrase II (bCAII) that could replace a polyclonal antibody. To further enhance the 
affinity or specificity of the PCC agent, I explore branching the peptide arms to develop branched 
PCC agents against bCAII. The developed branched capture agents have two to three fold higher 
affinities for the target protein.  
In the second part of my thesis, I describe the epitope targeting strategy, a strategy for 
directing the development of a peptide ligand against specific region or fragment of the protein. 
The strategy is successfully demonstrated by developing PCC agents with low nanomolar binding 
affinities that target the C-terminal hydrophobic motif of Akt2 kinase. One of the developed 
triligands inhibits the kinase activity of Akt. This suggests that, if targeted against the right 
epitope, the PCC agents can also influence the functional properties of the protein. The exquisite 
control of the epitope targeting strategy is further demonstrated by developing a cyclic ligand 
against Akt2. The cyclic ligand acts as an inhibitor by itself, without any iteration of the ligand 
discovery process. The epitope targeting strategy is a cornerstone of the IISCC technology and 
opens up new opportunities, leading to the development of protein detection agents and of 
modulators of protein functions. 
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1.1 Introduction 
As scientists develop increasing insight in the sciences of genomics and proteomics, a molecular 
picture of disease development and progression is gradually evolving1. It is essential to translate 
this vast resource of scientific knowledge into clinical platforms, so that one can envisage a 
future, each individual has his/her genetic and proteomic ‘fingerprints’ or biomarker patterns 
recorded. Monitoring this fingerprint will help not only in treatment, but also in disease 
prevention. While this picture of personalized medicine is a lofty goal, it is not an unattainable 
one if broken down into smaller, more attainable, goals. One of the challenges that must be 
addressed in realizing the goal is the development of a rapid, inexpensive and minimally invasive 
way of measuring biomarkers2. In my thesis I focus on a small but vital part of this challenge, 
developing a rapid, inexpensive way of measuring protein biomarkers. 
A biomarker is defined as an indicator of a specific biological state, which can be used to 
evaluate the risk of contraction or monitor the presence of a disease. Biomarkers can also provide 
guidance to targeted therapy and assess the response of therapy. While all the three different types 
of biomolecules, DNA, RNA and proteins, can act as biomarkers, protein biomarkers deserve a 
special mention3. Changes in the genetic level, such as DNA mutation, are manifested in changes 
in the protein levels. Additionally, proteins can undergo post-translational modifications, like 
phosphorylation, ubiquitination or glycolysation, that play key roles in modulating various 
biological processes like cell cycle, signal transduction4, which are almost always perturbed in 
disease development and progression. Current traditional diagnostics platforms use a limited 
number of biomarkers, typically 1-2, for prognosis e.g. measuring LDL for cholesterol. These 
assays typically use monoclonal antibodies in a Enzyme-Linked ImmunoSorbent Assay (ELISA) 
format. While monoclonal antibodies have levels of affinity and selectivity, they are expensive, 
especially if instead of one or two biomarkers one aims to measure a large panel of protein 
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biomarkers. The lack of stability of monoclonal antibodies with variation of temperature and 
humidity also adds significant additional costs to their shipping, handling, and storage. The third 
limiting aspect of monoclonal antibodies is their batch-to-batch variation in composition, which 
can alter the quantitative character of protein assays. Despite all these drawbacks, antibodies still 
remain the gold standard protein detection in different clinical and diagnostics platforms due to 
their high affinity and selectivity. 
To address the high demand for protein detection agents with antibody like sensitivity in 
diagnostics platforms while overcoming the inherent disadvantages of antibodies, scientists have 
tried to develop artificial alternatives to antibodies. There have been two approaches for this 
development. One is a protein engineering approach using an alternative small and robust protein 
scaffold with favorable folding and stability, and easy bacterial expression. Notable examples are 
affibody5 that is based on Z domain of protein A and DARPins that use ankyrin repeat motifs6. 
The second approach is chemical development of artificial protein capture agentsusing a bottom 
up approach. Artificial protein capture agents have been synthesized using a variety of using 
biological building blocks like nucleic acids7, peptides8, and carbohydrates9. Chemical 
approaches such as phage display10,11, nucleic acid aptamers12, mRNA display13, OBOC library14, 
have been used in to develop artificial antibody like molecules that have been used in detection, 
imaging, therapeutics etc. Phage display library technology has been extensively used to isolate 
both linear15 and cyclic peptide16 based protein capture agents. However phage display libraries 
are comprised of L-amino acids, so that peptides isolated from the library are protease sensitive.  
An alternative to the phage display library is the One-bead one-compound (OBOC)17 peptide or 
peptide mimetic libraries. While in OBOC libraries one can easily modulate chemical stability by 
incorporating artificial amino acids, OBOC libraries have smaller chemical diversities than phage 
libraries. Peptide ligand discovery is made typically with pentameric to octameric peptide 
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libraries, with lower diversity than phage display libraries. This is because in OBOC libraries the 
on bead peptides have to be highly pure, and coupling of each amino acid decreases the purity.  
To exploit the chemical flexibility of comprehensive, OBOC libraries of oligopeptides to 
develop high affinity, high selectivity protein capture agents, we married the OBOC peptide 
ligand discovery process with “in situ click chemistry”. “Click chemistry” describes a class of 
chemical reactions that quickly generate substances by joining small modular units18. Copper 
catalyzed Azide Alkyne Cycloaddition (CuAAC) is the quintessential ‘click’ reaction, where Cu 
acts as a catalyst in the reaction of azide and alkyne and create a 1,2,3 triazole linkage. A variant 
of click chemistry, ‘in situ click chemistry’19-21, is particularly relevant to our discussion. In ‘in 
situ click chemistry’ the biological target, rather than Cu, acts as the reaction catalyst. The target 
acts as a scaffold, bringing together complementary building block reagents to create the triazole 
linkage. In the demonstration of “in situ click” strategy, libraries of small molecules, based upon 
components of a known inhibitor, were used as building blocks and the assembled compound was 
this known inhibitor, targeting the active site of the target enzyme. It was observed that the 
reaction had high selectivity, selecting not only the right building blocks, but also the right 
orientation between the building blocks, to create a specific regioisomer.  
  Iterative In Situ Click Chemistry (IISCC)22,23 is a further development of this approach 
that we have developed for developing peptide based protein capture agents. Unlike the original 
approach that expanded upon a known inhibitor, in this approach we use large comprehensive 
libraries. This allows us to sample a much larger chemical space. In this process, the target is 
screened against OBOC peptide libraries to produce a peptide binder, typically having low 
micromolar affinity for the target protein.  This peptide is referred to as the 1° ligand or 
monoligand. The 1° ligand is modified with an alkyne or azide to form a monoligand anchor. The 
protein is treated with the monoligand anchor and then screened against an OBOC library 
containing the complementary click handle. The protein acting as a catalyst, selects a second 
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binder (2° ligand), and clicks it with the anchor peptide to form a biligand.  The biligand, 
modified with a new click handle (biligand anchor), is used, along with the protein, in the next 
round of ligand discovery. The process is then iterated to form a triligand, etc., until we achieve 
the desired levels of selectivity and affinity. The iterative nature of ligand discovery allows us to 
overcome the length limitation of OBOC peptide libraries. In the first demonstration of the IISCC 
technology, Agnew et al developed a triligand PCC Agent against bovine carbonic anhydrase II 
(bCAII) demonstrated that the developed PCC Agents could replace the antibody for carbonic 
anhydrase in protein assays like dot blots and ELISA. The target Carbonic anhydrase II was 
chosen as it has earlier been extensively characterized to study ligand-protein interactions. The 
protein has two distinct binding pockets and hence bind bivalent ligands21,24 
Chapter 1 of my thesis explores the IISCC technology to develop branched PCC agents 
against bovine carbonic anhydrase II. The reported PCC agents for bCAII had not been allowed 
to branch on the peptide backbone but was grown off at the C terminal or the N terminal. Hence 
the process did not exploit the architectural flexibility that arises from the modular nature of the 
PCC agents. If a PCC agent is allowed to evolve via branching on the 1° or 2° ligand, the 
architectural space scanned vastly increases. Peptide dendrimers containing branching amino acid 
cores and surface peptide chains have been reported to have higher binding affinities25. 
Constraining a peptide by branching or cyclizing it increases the geometric constraints and 
reduces the conformational entropy of the molecule26 which results in higher affinity. In the 
current work, starting from the same 1° ligand for bovine carbonic anhydrase, we allow 
development of branched PCC agents where one peptide arm is built off the backbone of another 
peptide arm. We discovered that branched ligands developed this way have affinities 2-3 times 
better than the original linear triligand reported. In ‘In situ click chemistry’ with protein as a 
catalyst, the protein may yield either anti (1,4), or syn (1,5) regioisomers a mixture of the two as 
the product. The multiligands that are produced in bulk and characterized, are synthesized 
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through CuAAC reaction, which means that in the characterized ligands the peptide arms are anti 
to each other and linked through a 1,4-triazole linker. 1,5 regioisomers are difficult to synthesize 
in bulk. We overcome this technical difficulty by developing a mimic of the 1,5 triazole linker. 
This allows us to characterize the PCC agents where the individual peptide arms are syn to each 
other. In the case of bCAII, we observe that the PCC agent with the 1,5 triazole linker mimic has 
higher affinity than the 1,4 triazole linked PCC agent.  
While one of the major advantages of the PCC capture agent is the generality of the 
approach, the original process of development does not allow one to target a specific region of the 
protein, unless one can start with a literature molecule that is known to bind to the region of 
interest such as the active site. Without this knowledge it is almost impossible to develop PCC 
agents that can distinguish between subtle variations of the protein structure. However, in 
diagnostics platforms it is often observed that the salient protein marker parameter is not the 
quantity of the protein but changes in the protein structure. Disease prognosis may require 
detection of phosphorylation, glycosylation and other post-translational modifications. Certain 
non-antibody protein capture agents have been developed to recognize specific post-translational 
modifications like acylation27. Nevertheless, there is no general strategy that can be used to 
develop these reagents. In chapter 3, we outline a general strategy to chemically develop a 
peptide based capture agent specifically targeting a certain region of the protein.  We describe the 
epitope targeting strategy and the development of peptide based PCC ligands that target the 
phosphorylated C-terminal hydrophobic motif of the protein Akt2. Akt, an AGC kinase, plays a 
central regulatory role in growth factor signaling, and serves as a key node in the 
phosphatidylinositol 3-kinase (PI3k) signaling pathway28,29.  In the fully active Akt2 protein, two 
residues T309 and S474 are phosphorylated. T309 is located near the ATP and substrate binding 
pocket. It is the primary phosphorylation site required for the activity of the kinase. S474 is 
located in the C terminal of Akt2, and is part of unstructured region of the protein. However, 
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S474 is known to be important for the kinase activity of the protein and phosphorylation at S474 
enhances the kinase activity 10-fold30.  In the context of current studies showing that ATP 
competitive inhibitors of Akt can cause hyperphosphorylation of the protein31, we thought it was 
worthwhile to find binders to the C terminal kinase regulatory domain, as such binders would 
have a high potential to regulate kinase activity. In this epitope targeting strategy, the target 
protein region is chemically modified to incorporate an azide/alkyne handle. The target, the C-
terminal polypeptide fragment of Akt2 (amino acids 450-481) with the phosphorylated Serine 474 
(p-S474), is modified with a dinuclear Zn (II) DPA type complex, which has an appended biotin 
label and an azide handle. The dinuclear Zn (II) DPA selectively binds to the phosphate anion and 
provides an initial in situ click reaction site adjacent to the phosphorylated residue azide 
functionality close to the hydrophobic motif. This phosphopeptide/metal complex is then 
subjected to an in situ click screen against a large one-bead-one-compound (OBOC) library of 
acetylene-containing 6-mer peptides to identify an initial (1o) peptide ligand. For an in situ click 
reaction, the binding target itself (here the 32-mer peptide) provides a highly selective catalytic 
scaffold for promoting the click reaction between an azide and an alkyne to produce a triazole 
linkage. The process of sequential in situ click chemistry is then utilized to expand the 1o ligand 
into a biligand, and then the biligand into two triligands.  
In chapter 4, we describe the assays used to choose the peptide arms, and characterize the 
final developed ligands in additional assays. The three triligand candidates have low nanomolar 
binding affinities. One triligand is selective for the Akt2 and over its homologous isoforms Akt1 
and Akt3. We also explore their effect on the kinase activity of Akt. Remarkably, the two 
triligands, sharing the same biligand fragment, were found to have opposite effects on the kinase 
activity of the Akt2 protein. While one of the ligands enhances the kinase activity of the protein, 
the other ligand inhibits the kinase activity. 
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In the epitope targeting strategy, we are trying to detect peptide-peptide interaction, 
which is typically weaker than peptide-protein interaction and tougher to detect. If the 1° ligand 
chosen has a high affinity for its peptide epitope, it significantly simplifies the epitope targeted 
PCC agent development process.  This led us to explore cyclic peptides, which have higher 
affinity and selectivity than their corresponding linear counterparts.  For demonstrating of this 
process, cyclic ligands were developed against the C terminal fragment from the protein Akt2, 
amino acids 450-481. In chapter 5 we describe the development of OBOC CuAAC cyclized 
peptide libraries, which are then screened against the peptide epitope to isolate a cyclic peptide 
monoligand. We demonstrate that the isolated monoligand binds to the peptide epitope and the 
full-length protein. The cyclic ligand has a low nanomolar binding affinity, rather than a 
micromolar binding affinity that is characteristic of a linear 1° ligand. The ligand is also found to 
inhibit the kinase activity of the protein. Future studies shall be done to develop the biligand and 
to study the effects in live cells. 
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Chapter  2: Development of branched capture agents against bovine 
carbonic anhydrase II 
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2.1  Introduction 
Biologically1,2 or chemically synthesized protein capture agents that can detect protein in 
diagnostics platforms and can be easily functionalized remain a very lucrative research area.  
Peptides discovered through phage display3-5, antibody or protein6 fragments7 and nucleic acid5,8,9 
aptamers represent some classes of protein capture agents. Each class of artificial capture agents 
have unique advantages and disadvantages6,10,11.In the past we have reported development of a 
new class of protein capture agents. An in situ protein-catalyzed multiligand capture agent was 
developed against bovine carbonic anhydrase II. The capture agent showed nanomolar binding 
affinity and could be used as an antibody substituent12. The PCC agent developed was linear, 
meaning that peptides, acting as modules, were joined either N terminal to N terminal or C 
terminal to N terminal. In the following chapter we extend the earlier work to develop branched 
capture agents against bCAII starting from the same monoligand peptide. Branching of peptides 
introduces geometric constraints to the PCC agent and reduces the conformational entropy of the 
molecule13, which should result in higher affinity. Branching of peptide have also been reported 
to increase the protease resistance14. In the current work we explore two approaches to find the 
most appropriate branching point of an anchor peptide towards branched ligands via in situ click 
screen. In one approach a branching point is introduced in the biligand stage through screening of 
peptide libraries containing azido-modified artificial amino acids at random positions. In the 
second approach, an amino acid within a linear biligand is replaced with an artificial amino acid 
containing an azide or acetylene functional group. Hydrophobicity and structural similarity are 
used as criteria for the replacement. The branched biligands are further used in triligand screens 
to develop branched triligands. Some of the branched triligands are found to have ~3 fold higher 
affinity than the linear triligand developed earlier. We also develop a mimic of the 1,5 
disubstituted 1,2,3 triazole linkage and determine if the 1,4 vs 1,5 orientation of the peptide arms 
in the developed multivalent ligands have any effect on the affinity for the protein.  
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2.2 Materials and Methods 
2.2.1 Materials  
  Fmoc D amino acids were purchased from Anaspec (San Jose, CA) and AAPPTec 
(Louisville, KY). TentaGel S-NH2 resin (diameter 90 µm, capacity 0.28 mmol/g) used in OBOC 
library construction was bought from Anaspec (San Jose, CA). Bulk peptide synthesis was done 
either on Biotin NovaTag™ resin (EMD) or Rink Amide MBHA resin (Anaspec). Peptide 
synthesis reagents NMP (1-methyl-2 -pyrrolidinone), HATU (2-(7-Aza-1H-benzotriazole-1-yl)-
1,1,3,3-tetramethylammonium hexafluorophosphate) and DIEA (N,N′-diisopropylethylamine) 
were bought from EMD Chemicals, Inc. (Gibbstown, NJ), ChemPep (Miami, FL), and Sigma-
Aldrich (St. Louis, MO) respectively. The target protein Bovine carbonic anhydrase II from 
bovine erythrocytes was bought from Sigma-Aldrich.  
2.2.2 Methods 
2.2.2.1 Synthesis of azide and alkyne containing artificial amino acids   
Artificial amino acids 21- 35 (Figure 2.7) containing either the free azide functionality or 
alkyne functionality were synthesized. Amino acids 21-27, 34-35 were synthesized following 
literature methods15-17. Amino acids 28-33 were developed by modification of literature 
methods18,19. The details of synthesis of amino acids 28-33 are as follows:  
 
Figure 2.1: Synthesis of unnatural amino acids containing PEGylated azide side chains.  
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To a solution of pre-dried diethyl acetamidomalonate (7.35g, 3.3mmol), sodium ethoxide 
solution (0.82 g, 12 mmol in 40 ml of ethanol) was added at ambient temperature and stirred for 2 
hours at 40oC. Azidoalkyliodide (4.0 mmol) was added and the reaction mixture was refluxed at 
85 °C for 24 hours. The mixture was extracted with ethyl acetate, washed with water and brine, 
dried over MgSO4 and then concentrated. Flash column chromatography (hexane:ethyl acetate = 
2:1) was performed to give a purified product diethyl 2-acetamido-2-(3-azidopropyl) malonate (> 
80%) as a clear oil. Diethyl 2-acetamido-2-(3-azidopropyl) malonate (2.6 mmol) was dissolved in 
35 ml of 10% NaOH solution and the mixture was refluxed for 4 hours. The solution was then 
acidified to pH = 2.0 with concentrated HCl and concentrated under reduced pressure. The 
residue was dissolved in 70 ml of H2O and refluxed for 4 hours. After cooling to ambient 
temperature, the mixture was acidified to pH 3.0 with 10% HCl solution and extracted with ethyl 
acetate. The organic layers were concentrated to give yellow oil, into which 54 ml of 2.0 N HCl 
solution was added. The mixture was refluxed for 2 hours and then concentrated in vacuum. The 
salt was then dissolved in a THF/H2O (55:45) mixture and NaHCO3 (10 eq.) was added with 
stirring at 0 °C. Fmoc-OSu (1.1 eq.) was added and the reaction mixture was stirred for 4 hours. 
THF was removed under reduced pressure and the resulting mixture was extracted with diethyl 
ether. The combined aqueous layers were acidified to pH 2.0 using concentrated HCl and 
extracted with ethyl acetate. The organic layers were washed with brine, dried over dried over 
MgSO4 and then vacuum concentrated to obtain the final product which was further purified by 
column chromatography to yield the white product. 
28 (n = 1):  
1H-NMR (400MHz, DMSO-d6): δ 1.77-1.85 (m, 2H), 1.94-2.02 (m, 2H), 3.30-3.60 (m, 6H), 4.04-
4.10 (m, 1H), 4.18-4.30 (m, 3H), 7.33 (t, 2H, J = 7.4 Hz), 7.41 (t, 2H, J = 7.4 Hz), 7.63 (d, 1H, J 
= 8.0 Hz), 7.72 (d, 2H, J = 7.4 Hz), 7.89 (d, 2H, J = 7.4 Hz), 12.85 (s, 1H). 
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13C-NMR (100MHz, DMSO-d6): δ 31.4, 47.1, 50.4, 51.2, 66.0, 67.1, 69.5, 120.6, 125.7, 127.5, 
128.1, 141.2, 144.3, 156.6, 174.4. 
29 (n = 1):  
1H-NMR (400MHz, CDCl3): δ 2.15-2.20 (m, 2H), 3.36-3.40 (m, 2H), 3.60-3.70 (m, 8H), 4.24 (t, 
2H, J = 6.4 Hz), 4.40-4.44 (m, 2H), 4.45-4.52 (m, 2H), 6.04 (bd, 1H, J = 7.2 Hz), 7.32 (t, 2H, J = 
7.4 Hz), 7.41 (t, 2H, J = 7.4 Hz), 7.61 (t, 2H, J = 7.4 Hz), 7.77 (d, 2H, J = 7.4 Hz). 
13C-NMR (100MHz, CDCl3): δ 31.0, 31.4, 47.2, 50.7, 52.5, 67.0, 67.9, 69.8, 70.3, 120.0, 125.1, 
127.1, 127.7, 141.3, 143.8, 156.2, 175.0. 
Figure 2.2: Modification of D-phenyl alanine with an azido/acetylene group to synthesize 
amino acids 30 -33. 
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dissolved in 40% aqueous THF. NaHCO3 (10 eq.) and Fmoc-OSu (1.1 eq.) were added 
sequentially and stirred overnight. After removal of THF, diethyl ether was added to extract 
unreacted Fmoc-Osu. After discarding the organic layers, the pH of the aqueous solution was 
adjusted to 2.0 by adding 2M HCl solution. The product was extracted with ethyl acetate and then 
purified through column chromatography using DCM: MeOH (50:1). 
30: 1H-NMR (400MHz, CDCl3): δ 2.03 (q, 2H, J = 6.4 Hz), 3.07 (dd, 1H, J = 14.4, 6.4 Hz), 3.16 
(dd, 1H, J = 14.4, 5.2 Hz), 3.50 (t, 2H, J = 6.4 Hz), 3.98 (t, 2H, J = 6.0 Hz), 4.21 (t, 1H, J = 7.2 
Hz), 3.36 (dd, 1H, J = 10.8, 6.8 Hz), 3.16 (dd, 1H, J = 10.8, 6.8 Hz), 4.65-4.70 (m, 1H), 5.23 (bd, 
1H, J = 8.0 Hz), 6.82 (d, 2H, J = 8.4 Hz) , 7.17 (d, 2H, J = 8.4 Hz), 7.31 (t, 2H, J = 7.4 Hz), 7.41 
(t, 2H, J = 7.4 Hz), 7.55 (t, 2H, J = 7.4 Hz), 7.78 (d, 2H, J = 7.4 Hz). 
13C-NMR (100MHz, CDCl3): δ 28.8, 36.9, 47.1, 48.2, 54.7, 64.4, 67.1, 114.6, 120.0, 125.1, 
127.1, 127.7, 127.8, 130.4, 141.3, 143.6, 143.7, 155.8, 157.9. 
31: 1H-NMR (400MHz, CDCl3): δ 1.40-1.52 (m, 4H), 1.60-1.68 (m, 2H), 1.76-1.82 (m, 2H), 
3.04-3.20 (m, 2H), 3.28 (t, 2H, J = 6.8 Hz), 3.92 (t, 2H, J = 6.4 Hz), 4.21 (t, 1H, J = 7.2 Hz), 
4.34-4.40 (m, 1H), 4.43-4.49 (m, 1H), 4.65-4.71 (m, 1H), 5.21 (bd, 1H, J = 8.0 Hz), 6.82 (d, 2H, 
J = 8.4 Hz) , 7.17 (d, 2H, J = 8.4 Hz), 7.31 (t, 2H, J = 7.4 Hz), 7.41 (t, 2H, J = 7.4 Hz), 7.55 (t, 
2H, J = 7.4 Hz), 7.78 (d, 2H, J = 7.4 Hz). 
13C-NMR (100MHz, CDCl3): δ 23.0, 23.7, 25.7, 26.5, 28.9, 30.3, 47.1, 51.4, 67.1, 67.7, 114.6, 
120.0, 125.1, 127.1, 127.8, 130.4, 141.3, 143.7, 158.3. 
32:1H-NMR (400MHz, CDCl3): δ 3.04-3.18 (m, 2H), 3.41 (t, 2H, J = 4.8 Hz), 3.74 (t, 2H, J = 4.8 
Hz), 3.85 (t, 2H, J = 4.8 Hz), 4.10 (t, 2H, J = 4.8 Hz), 4.37 (dd, 1H, J = 10.8, 6.8 Hz), 4.46 (dd, 
1H, J = 10.8, 7.2 Hz), 4.62-4.70 (m, 1H), 5.27 (bd, 1H, J = 8.0 Hz), 6.85 (d, 2H, J = 8.8 Hz) , 
7.06 (d, 2H, J = 8.8 Hz), 7.31 (t, 2H, J = 7.4 Hz), 7.41 (t, 2H, J = 7.4 Hz), 7.55 (t, 2H, J = 7.4 
Hz), 7.79 (d, 2H, J = 7.4 Hz). 
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13C-NMR (100MHz, CDCl3): δ 36.9, 47.1, 50.7, 54.7, 67.1, 67.3, 69.8, 70.2, 114.8, 120.0, 125.1, 
127.1, 127.8, 130.4, 141.3, 143.7, 155.8, 157.9, 175.8 
33: 1H-NMR (400MHz, CDCl3): δ 3.03-3.18 (m, 2H), 3.38 (t, 2H, J = 4.8 Hz), 3.65-3.70 (m, 4H), 
3.71-3.76 (m, 2H), 3.83-3.88 (m, 2H), 4.07-4.11 (m, 2H), 4.21 (t, 1H, J = 6.8 Hz), 4.36 (dd, 1H, J 
= 10.8, 6.8 Hz), 4.45 (dd, 1H, J = 10.8, 7.2 Hz), 5.33 (bd, 1H, J = 8.0 Hz), 6.84 (d, 2H, J = 8.8 
Hz) , 7.05 (d, 2H, J = 8.8 Hz), 7.31 (t, 2H, J = 7.4 Hz), 7.41 (t, 2H, J = 7.4 Hz), 7.55 (t, 2H, J = 
7.4 Hz), 7.79 (d, 2H, J = 7.4 Hz). 
13C-NMR (100MHz, CDCl3): δ 36.9, 47.1, 50.6, 54.7, 67.0, 67.3, 69.8, 70.1, 70.7, 70.8, 114.7, 
120.0, 125.1, 127.1, 127.8, 130.4, 141.3, 143.8, 155.8, 157.9, 175.4, 176.8. 
2.2.2.2 Procedure for peptide synthesis  
Peptides were synthesized using standard Solid Phase Fmoc chemistry (SPPS)20 either 
manually or automatically. Peptides were synthesized on Rink Amide AM resins (Anaspec, 
loading = 0.31 mmol/g), Biotin Novatag Resin (EMD Biosciences, loading 0.5 from mmol/g), 
and Rink Sieber Amide resin (Anaspec, loading = 0.4 mmol/g) on a 200 mg scale. Peptides were 
manually synthesized in fritted polypropylene tubes using a 180° shaker (St. John Associates; 
Beltsville, MD). A 24-port SPE vacuum manifold system (Grace; Deerfield, IL) was used for 
draining the coupling and deprotection solutions. Automated synthesis was done using the Titan 
357 (AAPPTec) automated peptide synthesizer. Before the peptide synthesis, the resin was 
swelled in NMP for 2 hours. For coupling amino acids to the resin, it was treated for 30 minutes 
with 2 equivalents of an Fmoc protected amino acid, (0.2 M in NMP), 2 equivalents of TBTU 
(0.2 M solution in NMP), and 5 equivalents of DIEA (0.2 M solution in NMP). For removal of 
the Fmoc group from the N terminal, the resin was treated with 20% pyridine in NMP for 15 
minutes twice. In between the coupling and deprotection steps, the resin was washed five times 
for 1 minute with NMP. For N- terminal acylation, the peptide containing resin was swelled in 
DMF and treated with 5:6:10 solution of acetic acid, 2,6 lutidine and DMF for 10 minutes twice. 
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Following the treatment the excess reagent was removed by multiple washes with DMF. For 
peptide cleavage off the resin, the resin was treated with a trifluoroacetic acid cleavage cocktail 
(TFA/water/triisopropylsilane (TIS) (95/2.5/2.5, v/v/v)) mixture at room temperature for 2 hours. 
The cleavage solution was concentrated and then added drop-wise into ice-cold diethyl ether to 
precipitate the peptide. The resulting crude peptides were lyophilized. All the peptides were 
purified using a gradient of double distilled water and HPLC grade acetonitrile and 0.1% TFA on 
the RP-HPLC (Beckman Coulter System Gold 126 Solvent Module and 168 Detector) using a 
C18 reversed phase semi-preparative column (Phenomenex Luna 10 µm, 250 × 10 mm).  
Protocol for on bead copper catalyzed azide alkyne cycloaddition (CuAAC) click reaction:  
On bead Cu catalyzed click reactions were performed with the azide on bead and the 
alkyne in solution. The resin was treated with 2 equivalents of the relevant alkyne, 1.5 equivalents 
of CuI (Sigma) and 2.5 equivalents of ascorbic acid (Sigma), in a solution of 20% piperidine in 
DMF. The reaction was performed overnight at room temperature. The excess copper was 
removed from the resin by washing extensively with a Cu chelating solution (5% (w/v) sodium 
diethyl dithiocarbamate, 5% (v/v) DIEA in DMF). 
Synthesis of biotin tagged peptides:  
Biotin was incorporated at the C terminal for all the peptides, with a polyethylene glycol 
between the biotin tag and the rest of the peptide sequence. The peptides were synthesized either 
by directly using biotin novatag resin (which incorporates a biotin on the C terminal of the 
peptide) or by appending a biotin on the side chain of a lysine on Rink Amide MBHA resin. For 
the later method,  Fmoc-lysine(Mtt)-OH (Mtt = 4-methyltrityl) was coupled to Rink Amide resin 
using standard SPPS chemistry. The Mtt group was selectively removed by three consecutive 
washes with trifluoroacetic acid (3%), triisopropylsilane (3%) and DCM (94%). 1.5 equivalents 
of Biotin-NHS and 5 equivalents of DIEA were added to the resin Fmoc-(PEG)2-CO2H (20 
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atoms, EMD Biosciences) was coupled to the resin to introduce a polyethylene glycol (PEG)  
spacer. The synthesized peptides were purified to > 98% purity. 
2.2.2.3 Measurement of the Relative Hydrophobicity Coefficients of amino acids 
 To compare the relative hydrophobicities of the synthesized artificial amino acids with 
natural amino acids, a literature method was adapted21. Briefly, a series of Ac-X-GLF-OH 
peptides were synthesized (X is the natural or unnatural amino acid) and their retention times 
were measured using an autosampler equipped Waters Acquity UPLC system (Waters Acquity 
UPLC® BEH C18 column, flow-rate of 0.3 ml/minutes, temperature 25°C, eluent of 10% 
acetonitrile and 0.1% TFA in water). The hydrophobicity coefficients of the amino acid X in the 
synthesized peptides were calculated as the retention time of the X-substituted peptide minus the 
retention time of Ac-GGLF-OH peptide. The relative hydrophobicity coefficients are presented in 
Figure 2.8.  
2.2.2.4 Construction of Peptide Libraries 
Randomized OBOC libraries of penta or heptapeptides were synthesized using an 
automatic synthesizer Titan 357 (AAPPTec) via standard split-and-mix methods, on TentaGel S-
NH2 beads. Unless otherwise specified, non-natural D-stereoisomers were used at every possible 
position in the peptide sequence. For all the coupling steps, standard SPPS method with Fmoc 
chemistry was used. The resin was swelled in NMP for 2 hours in a big Collective Vessel (CV) 
and divided into multiple equal-mass aliquots for the cycles of coupling and deprotection with 
different amino acids in the smaller Reaction Vessels  (RV). For libraries used at IBN, Fmoc-
methionine was coupled to the entire resin in the first coupling step to make the library MALDI-
TOF compatible. The amino acid side-chain protective groups were then removed by treatment 
with TFA cleavage cocktail mixture for 2 hours. The on bead peptide library was washed with 
DCM, methanol and water, and stored. The peptide libraries used for various screens are 
summarized in Table 2.1. 
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Table 2.1: One Bead One Compound (OBOC) peptide libraries used in screens. 
Library Sequence Amino acids used Number of 
unique 
sequences 
A X1X2X3X4X5X6-
TG 
Xi= D-Trp, D-Lys, D-Ile, Gly, D-Leu, D-Val, 
D/L- azidolysine 
117649 
B X1X2X3-D/L-Az4-
X5X6-D-Met-TG 
Xi = D-Trp, D-Lys, D-Leu, D-Val, D-Ile, Gly 15552 
C X1X2kX4-D/L-
Az4-X6w-D-Met-
TG 
X1= all 18 D amino acids except D Met and D-
Cys; X2= D-Lys(Alloc)-OH, D-Trp, D-Val; X4= 
D-Arg, D-Asn, D-Gln, D-Asp, D-Lys, D-Ser, D-
Thr, D-His, D-Ala, Gly, D-Val, D-Trp; 
X6 = D-Arg, D-Asn, D-Gln, D-Asp, D-Lys, D-Ser, 
D-Thr, D-His, D-Ala, Gly, D-Leu, D-Phe 
 
15552 
D Acetyl-D-Pra-
X1X2X3X4X5X6-L-
Met-TG 
D-Pra = D-Propargylglycine,; Xi = D-Ala, Gly, D-
Leu, D-Ile, D-Val, D-Phe, D-Trp, D-Arg, D-His, 
D-Lys, D-Asp, D-Glu, D-Asn, D-Gln, D-Ser, D-
Thr, D-Tyr, D-Pro 
 
34012224 
E X1X2X3X4X5X6-L-
Met-TG 
X1= D-Lys, D-Arg, D-Val, D-Leu, D-Phe, D-Ile, 
D-Tyr, D-Trp; X2 = D-Ile, D-Arg, D-Phe, D-Val, 
D-Leu, D-Lys, D-Trp, D-Tyr; X3= D-Phe, D-Arg, 
D-Ile, D-Val, D-Leu, D-Lys, D-Thr; X4 = D-Tyr, 
D-Phe, D-Arg, D-Trp, D-Val, D-Lys, D-Ile, D- 
Leu X5 = D-Arg, D-Ile, D-Lys, D-Phe, D-Val, D-
Tyr, D - His, D-Asn; X6 = D-Arg, D-Lys, D-Phe, 
D-Tyr, D-Val, D-Trp, D-His, D-Ile 
 
 262144 
F D/L-Az4- 
X1X2X3X4X5-TG 
Xi = all 18 D amino acids except D-Met and D-
Cys 
 
3,779,136 
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2.2.2.5 Screening procedures  
For screens with the florescent labeled protein, bCAII was labeled with Alexa Fluor 647 
(Microscale Protein Labeling Kit, Invitrogen) following the manufacturer’s protocol. The 
different screens for biligand and triligands are summarized in Table 2.2. Details of each type of 
screen i.e., target, or product, and each type of sorting, i.e., automatic or manual is provide below.  
 
Table 2.2: Summary of screens for the development of branched PCC agents for bovine 
carbonic anhydrase II. 
 
Screen Library bCAII  concentration 
Peptide 
anchor 
Peptide 
concentration 
Type of 
Screen 
Type of 
sorting 
Ligand/ 
motif 
Isolated 
BB1 A 10 nM 37 20 µM target manual xxx-Az4-xx 
BB2 B 10 nM, 1 nM and 500 pM 37 
20 µM, 2 µM, 
1 µM  
target manual 
x-k-x-
Az4-x-
w 
BB3 C 10 nM 37 40 µM target manual 38, 39 
TRI1 D 10 nM 42 20 µM target automated N/A 
TRI2 E 10 nM 42 20 µM target automated     45, 46  
TRI3 F 10 nM 40 20 µM product manual 48, 49, 50, 51 
 
In situ click target screen: 
  Nanomolar solutions of Alexa Fluor 647-labeled bCAII (PBS, pH 7.4, 0.1% Tween-20, 
0.1% bovine serum albumin (BSA), 0.05% NaN3) was pre-incubated for 2 hours with the 
micromolar solutions of the corresponding anchor peptide (table 2.2) in binding buffer for 2 hours 
at 25oC in a polypropelene vessel. 200 mg of the relevant OBOC peptide library was swelled in 
the binding buffer in a separate vessel for 1 hour at 25oC. The pre-incubated solution of Alexa 
Fluor® 647-labeled bCAII and the biligand peptide anchor 40 were added to the equilibrated on 
bead peptide library. The library was incubated for ~16 hours at 25oC. Non-specifically bound 
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proteins were eliminated by multiple washes, first with the binding buffer and then with 
0.1%Tween 20 in PBS. The details of each individual screen are tabulated in table 2.2. 
Automated sorting of fluorescent protein:  
The assayed library was transferred into the sample vessel of a COPAS Plus (Union 
Biometrica) automated bead sorter, and diluted with 200 ml of PBS buffer (pH=7.4). A two-step 
sorting was applied. The first sorting was performed at high flow rate (> 80 beads per seconds) to 
sort out 1~2% of beads according to fluorescence intensity. The sorted bright beads were washed 
with DI water several times, transferred into the sample vessel, and diluted with 200 ml of DI 
water.  The second sorting was carried out at low flow rate (5 to 10 beads per second). In the 
second sorting, positive beads were directly sorted into a 96 titer well plate with conical-shaped 
wells. Sequencing of these beads was performed with MALDI-TOF/TOF and the semi-automated 
algorithm. 
Manual sorting of fluorescent protein:  
Following the screen and washes, the library was transferred to glass microscope slides 
and imaged using the GenePix 4200 array scanner (λex = 635 nm). The beads with the highest 
fluorescence intensities were considered hit beads and picked up manually using a glass 
micropipette. The picked beads were washed with 7.5 M guanidium hydrochloride (pH= 2.0) for 
1 hour followed by ten washes with double distilled water. Each bead was loaded on a cartridge 
on the Edman Sequencer (494 Procise cLC Sequencer, Applied Biosciences).  
In situ click product screen: 
 Bovine carbonic anhydrase II was incubated with ~2000x concentrated biotinylated 
anchor peptide overnight at 25 oC. The OBOC peptide library is swelled in the binding buffer 
overnight and then added to the preincubated protein solution. The screen was done for 7.5 hours 
at room temperature, followed by washes with the binding buffer, wash buffer 1 (PBS + 0.05% 
NaN3 + 0.1% Tween 20) and PBS. The beads were treated with 7.5 M guanidium hydrochloride 
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(pH = 2) for an hour and washed ten times with Millipore water. The beads were swelled back in 
binding buffer and incubated for an hour with a 1:10,000 diluted solution of anti-biotin mAb-
alkaline phosphatase (Sigma Aldrich) in the binding buffer. The beads were washed multiple 
times with the wash buffer and PBS. The beads in AP buffer (100mM Tris-HCl [pH 9.0], 150mM 
NaCl, 1mM MgCl2) were transferred to plastic petri dishes. 10 ml of BCIP solution  (33 µl BCIP/ 
10 ml AP buffer) was added to each petri dish. After 30 minutes, beads that have anti-biotin 
mAb-alkaline phosphatase binding to them turn turquoise due to the reaction of BCIP with the 
alkaline phosphatase. These beads were picked up manually using a micropipette and decolorized 
by washing with dimethyl formamide. Following treatment with 7.5 M guanidium hydrochloride 
(pH= 2.0) for 1 hour and stringent water washes, the beads were equilibrated in binding buffer. 
The library was then treated with biotin saturated anti-biotin –alkaline peroxide antibody. After 
an hour, the beads were washed as in the previous screen and treated with BCIP solution.  Due to 
ligand competition, the beads that bind to the biotin-binding site of the antibody were colorless in 
this screen while the nonspecific binders to the antibody turned turquoise. The colorless beads 
were picked up manually, washed with 7.5 M guanidium hydrochloride (pH= 2.0) for 1 hour 
followed by ten washes with Millipore water. Each bead was separately loaded on an Edman 
Sequencer cartridge and sequenced on the Procise sequencer.  
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Table 2.3: Hit sequences from the first biligand screen BB1. 
The library A of form X1X2X3X4X5X6-TG (where Xi= D-Trp, D-Lys, D-Ile, Gly, D-Leu, D-Val, 
D/L- azidolysine TG = tentagel S NH2 resin, diversity 117649) is screened with anchor peptide 
37 with the Alexa-647 labeled bCAII protein.  
 
X1 X5 X3 X4 X5 X6 
I f k Az4 v w 
i k v Az4 i w 
f k w Az4 i w 
v k v Az4 i w 
w k v Az4 i w 
w k l Az4 i w 
f k f Az4 f f 
Az4 k f Az4 i w 
Az4 k w G G l 
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Table 2.4: Hit sequences from the second generation biligand screen BB2. 
The library B of form X1X2X3-D/L-Az4-X5X6-D-Met-TG (where Xi = D-Trp, D-Lys, D-Leu, D-
Val, D-Ile, Gly, Met=L-Methionine, TG = tentagel S NH2 resin, 15552 unique sequences) is 
screened with anchor peptide 37 with the Alexa-647 labeled bCAII protein in the biligand screen. 
 
Protein 
concentration 
X1 X2 X3 Az4 X5 X6 
10 nM w k v Az4 l w 
10 nM v k v Az4 i w 
10 nM w k l Az4 i w 
10 nM i k w Az4 f w 
10 nM w k f Az4 i w 
10 nM v k w Az4 i w 
10 nM w k i Az4 v w 
10 nM v k w Az4 i w 
10 nM i k f Az4 i w 
10 nM f k f Az4 f w 
10 nM v k w Az4 f w 
1 nM v k w Az4 f w 
500 pM w k v Az4 l w 
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Table 2.5: Hit sequences from the third generation biligand screen BB3. 
The library C of form X1X2kX4-Az4X6w-D-Met-TG (where X1= all 18 D amino acids except D 
Met and D-Cys; X2= D-Lys(Alloc)-OH, D-Trp, D-Val; X4= D-Arg, D-Asn, D-Gln, D-Asp, D-
Lys, D-Ser, D-Thr, D-His, D-Ala, Gly, D-Val, D-Trp; X6 = D-Arg, D-Asn, D-Gln, D-Asp, D-Lys, 
D-Ser, D-Thr, D-His, D-Ala, Gly, D-Leu, D-Phe) is screened with anchor peptide 37 and Alexa-
647 labeled bCAII protein . 
 
X1 X2 k X4 Az4 X6 w 
k w k w Az4 l w 
r v k w Az4 i w 
v w k v Az4 i w 
k w k v Az4 l w 
a v k v Az4 l w 
i v k w Az4 l w 
i w k v Az4 f w 
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Table 2.6: Hit sequences from the first generation triligand screen TRI1  
Library D of form Acetyl-D-Pra-X1X2X3X4X5X6-L-Met-TG (where D-Pra = D-Propargylglycine,; 
Xi = D-Ala, Gly, D-Leu, D-Ile, D-Val, D-Phe, D-Trp, D-Arg, D-His, D-Lys, D-Asp, D-Glu, D-
Asn, D-Gln, D-Ser, D-Thr, D-Tyr, D-Pro)  is screened against bCAII- biligand 42 complex. 
 
1 vgvwfk 38 nyfkrr 77 hrfyrr 
2 viifkr 39 fttlvk 78 rGfykr 
3 wklwfr 40 lrfyli 79 yryrlr 
4 hiifnk 41 aiflrr 80 klkyrr 
5 alfiir 42 kyrylr 81 srryry 
5 hdtfvr 43 rfrrfa 82 rlfyth 
6 afffrl 44 ldnvvk 83 Gwyvrr 
7 hiryrk 45 ylfflr 84 krwwnr 
7 vwtygh 46 lvallk 85 frkrhr 
8 iwvryd 47 lrlllr 86 tiiyrh 
9 vflrnv 48 kwrirl 87 kvyfnr 
10 nvarhp 49 ffrtlv 88 tllykk 
11 lrlyfr 50 iviwkr 89 rrfrlr 
12 rfrlwl 51 kwrhwr 90 yyrfrk 
13 vkiyvr 52 iaiwlr 91 khyrrw 
14 kiyvrf 53 llvvyr 92 kiifsr 
15 vvtsvr 54 nwkryr 93 rvvwfr 
16 vrlylk 55 llhvfr 94 vklflk 
17 rilfhw 56 rfwklk 95 frvwfg 
18 kwyfyr 57 sryrhr 96 ryffkw 
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19 yifflr 58 kfhrrk 97 ftvllr 
20 lraylr 59 yafflr 98 riyvrv 
21 wrrfrr 60 kfyyrv 99 lrkwlw 
22 ytGlfk 61 kiryfr 100 rfvkvf 
23 pypyl 62 nwkwrk 101 wpherd 
24 nrGnhr 63 khwrrr 102 pfdlw 
25 Iiiyrs 64 rkawlr 103 fyyrk 
26 yylvkr 65 fitrkf 104 pwfwG 
27 llhltk 66 kwvver 105 rfvkvf 
28 wpvpvf 67 ywlvkr 106 fkrkir 
29 frvysf 68 lffrwv 107 wriyir 
30 nfyyri 69 fafyvr 108 lfirly 
31 rwklrr 70 wirirk 109 vfvkkl 
32 kwtrei 71 hifirk 110 llrlay 
33 wirGfy 72 rifvfr 111 rlrfhk 
34 vyrkyk 73 llfyrk 112 prfyky 
35 iyifrk 74 hyrkkw 113 rvkwkk 
36 yrwrkf 75 ywflkk   
37 rkywkr 76 fkkyyr   
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Table 2.7: Hit sequences from the second generation triligand screen TRI2  
Library E of form X1X2X3X4X5X6-L-Met-TG (X1= D-Lys, D-Arg, D-Val, D-Leu, D-Phe, D-Ile, 
D-Tyr, D-Trp; X2 = D-Ile, D-Arg, D-Phe, D-Val, D-Leu, D-Lys, D-Trp, D-Tyr; X3= D-Phe, D-
Arg, D-Ile, D-Val, D-Leu, D-Lys, D-Thr; X4 = D-Tyr, D-Phe, D-Arg, D-Trp, D-Val, D-Lys, D-
Ile, D- Leu X5 = D-Arg, D-Ile, D-Lys, D-Phe, D-Val, D-Tyr, D - His, D-Asn; X6 = D-Arg, D-Lys, 
D-Phe, D-Tyr, D-Val, D-Trp, D-His, D-Ile) is screened against Alexa-647 labeled bCAII in 
presence of biligand 42.  
 
 
1 yrlfvr 18 lilfnr 35 yklffr 
2 kyfakf 19 lklwfk 36 vklwfk 
3 vrlffk 20 kyyfrf 37 kyffrf 
4 vklwlk 21 lklwlk 38 kyffrf 
5 rfwfkw 22 vklwfk 39 yvtfvk 
6 yirnrr 23 ykifvr 40 kyffrf 
7 kyffrf 24 kyffrf 41 yrrfri 
8 kyffkf 25 kfffrv 42 vkifvr 
9 iitfnr 26 ifyrh 43 lilfnr 
10 vrlffk 27 vklfvr 44 rfffrv 
11 rifvri 28 kiyffr 45 ryflrf 
12 kiyffr 29 kfffr 46 irlflk 
13 kfffri 30 iklwlr 47 vivfnr 
14 ivlfnr 31 irlwlk 48 ivkfvr 
15 lrlwlk 32 fkifvr 49 kwyffr 
16 kffyrf 33 lrfflk 50 kyffrf 
17 rkrfrh 34 lrkfri   
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Table 2.8: Hit sequences from the first generation screen TRI3 using the product screening 
method. 
The library F of form D/L-Az4- X1X2X3X4X5-TG (Xi = all 18 D amino acids except D-Met and 
D-Cys) is screened with biligand anchor peptide 40 with the Alexa-647 labeled bCAII protein in 
the triligand screen. 
 
Az4 X1 X2 X3 X4 X5 
Az4 h d t f y 
Az4 h d t G f 
Az4 h d e G G 
Az4 y s q w a 
 
2.2.2.6 Dot blots  
The affinity of the capture agents for bCAII was demonstrated through dot blot 
experiments in 5% nonfat dry milk in TBST [25 mM Tris, 150 mM NaCl, 2 mM KCl, 0.1% 
Tween 20 (pH 7.0)]. A bCAII stock solution (10 mg/mL) was prepared in PBS buffer (pH 7.4). A 
dilution series of bCAII solution was applied to a nitrocellulose membrane, typically ranging 
from 1 µg to 20 ng per spot. The membrane was blocked at room temperature for 1 hour in 5% 
nonfat milk/TBST, which was then washed three times with TBST for 10 minutes each. A 
biotinylated peptide ligand solution was prepared at 100 nM or 1 µM in 0.5% nonfat milk/TBST 
and incubated over the membrane for 1 hour at room temperature. After washing three times with 
TBST for 10 minutes, the membrane was incubated with 1:3000 streptavidin-HRP (Abcam) in 
0.5% milk/ TBST for 1 hour followed by subsequent washing with TBST for 10 minutes. The 
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resulting membrane was detected using the chemiluminescent reagents (Amersham ECL plus 
Western blotting detection reagents, GE Healthcare).  
2.2.2.7 ELISA with PCC agent as capture agent  
Streptavidin coated 96 well plates were washed three times with 0.1% BSA/TBST. 100 
µl of 200 nM solution of the biotinylated capture agent (made by dilution in 0.1% BSA/TBST of 
1 mM DMSO stock) was added to each well and incubated for 2 hours with shaking at room 
temperature. The wells were then washed three times with 200 µl of 0.1% BSA/TBST. 100 µl of 
His6 tagged recombinant carbonic anhydrase II protein solution, (from 10 µM to 1 nM in 0.1% 
BSA/TBST) was added to the wells. After overnight incubation of the plate at 4°C, each well was 
washed three times with 0.1% BSA/TBST. 100 µl of 1:1000 diluted anti-His6 mouse monoclonal 
antibody (Abcam) was added to each well and incubated with shaking for an hour at 4°C. 
Following three washes with 0.1% BSA/TBST, 100 µl of a 1:10,000 diluted solution of anti –
mouse IgG goat antibody conjugated with horseradish peroxidase enzyme (Abcam) was added 
and incubated for one hour at 4°C. After one hour the wells were washed five times with TBST 
and then 100 µl TMB (3,3’,5, 5’-tetramethylbenzidine) substrate (KPL) was added per well. 
Upon color development, each well was quenched with 100 µl of 1 M sulfuric acid in the order 
the TMB substrate was added. The absorbance at wavelength 450 nm was measured using a 
Spectramax ELISA plate reader. 
2.3  Results and discussion 
The PCC agent can be visualized as a multivalent binding agent that links several non-
competitive weak affinity peptide ligands to allow cooperative binding. We have developed in the 
past a linear triligand capture agent 44 against bovine carbonic anhydrase II (bCAII). Starting 
with the development of a weak peptide binder (with high micromolar dissociation constant) 36, a 
specific and selective multiligand peptide binder with high nanomolar affinity had been 
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developed. The peptide ligands had been selected through screens such that they could be linked 
linearly from N terminal to C terminal. In the current work, we explore the different 
connectivities of the peptide ligands to create branched peptide multiligands for bCAII starting 
with the same monomeric peptide binder. Two different methods of developing a branched 
bivalent PCC agent are explored. In the first method, the reported peptide 36 is retained as the 
monoligand and a new 2° peptide arm is discovered thorough screening. In the second method, 
the earlier reported linear biligand 41 is modified in the 2° ligand arm. The newly developed 
branched biligands are used to screen for branched trivalent PCC agents. It is explored if the 
variation in connectivity of the peptide arms in the PCC agent has any positive effect on the 
affinity of the ligand for the bCAII protein. 
2.3.1 Development of branched biligand using randomized azide library 
In the previous work, the primary peptide binder 36 to the protein that had been obtained 
via two-generation screens, first against a comprehensive random library, and then against a 
smaller focused library. This ligand 36 had been modified with D-propargylglycine at the C 
terminal to form the anchor ligand, 37, and used as the anchor peptide in the linear biligand 
screens. To develop a branched biligand containing the same primary ligand, we utilize the 
highest occurring amino acids from the linear library screens to develop a small focused library. 
To allow the protein to scan the entire conformational space the azidolysine is used as an amino 
acid component like all others. This results in the synthesis of an OBOC heptapeptidic library 
with a random number and random position of the azidolysine (library A). The library was 
screened against 10 nM Alexa 647-labelled bCAII pretreated 20 µM peptide 37. After buffer 
washes, the beads with the highest fluorescent intensities were manually picked up. Out of the ten 
sequences containing azidolysine, nine contained one azidolysine, while one sequence had two 
azidolysines Amino acid D/L-azidolysine was conserved at X4 (Table 2.3). This suggested that 
the protein actually prefers the in situ click occurring not end to end but from one end of the 
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anchor to the middle of the second peptide arm. X2 and X6 positions of the hit sequences were 
also found to be highly conserved. A second focused library was synthesized, where the position 
of the D/L-azidolysine was fixed at X4. The library was screened against three different 
concentrations (10 nM, 1 nM and 500 pM) of Alexa 647-labeled bCAII in presence of peptide 37. 
The beads with highest fluorescence intensity were picked. This yielded eleven beads from the 10 
nM screen, and one bead each from the 1 nM and 500 pM screens (Table 2.4). The trends noticed 
in the first screen were even more noticeable in this screen, yielding two motifs, wkX-Az4-Xw 
and vkX-Az4-Xw. Biligands 38 and 39 were synthesized in which vkw-Az4-lw and wkv-Az4-lw 
were clicked to the peptide 37. 
To find the preference of the protein for further branching, the protein was screened with 
a third heptameric focused library. The aim of this library was to increase the length of the second 
peptide arm while simultaneously looking at the selectivity of the protein for branching at X5 
position by incorporation of D-Lys(Alloc)-OH. In situ click screens of two copies of the OBOC 
library with 10 nM bCAII pretreated with 40 µM anchor, after buffer washes, was imaged and the 
highest fluorescent intensity beads manually picked. The sequences of the beads are presented in 
Table 2.5. The amino acid at X5 was always D-Trp or D-Val, indicating a strong preference of 
these two amino acids at this position. A hit sequence k(alloc)-wkv(Az4)lw obtained twice within 
the hit sequences was chosen as the candidate to further extend the second peptide arm. The 
alkyne functionality was incorporated on the side chain of the N terminal D-Lys by coupling 
Fmoc-D-Pra to the lysine side chain.  
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Figure 2.3: Molecular structures of the reported monoligand 36 and the monoligand anchor 
37 used in the branched biligand screen. 
 
 
Figure 2.4: Schematic representation of target screen against bovine carbonic anhydrase II 
using OBOC library with multiple azides for developing a branched biligand.  
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Figure 2.5: Motifs obtained by screening against bovine carbonic anhydrase II in presence 
of monoligand anchor peptide 37. 
Screening against a library with variable number and position of azides, it is observed that the 
protein favors one azidolysine at X4. Screens against focused library B yield motifs wkXAz4Xw 
and vkXAz4Xw. Screen against a further focused library C containing these two motifs yields the 
final biligand anchor arm k(alloc)-wkv-Az4-lw.  
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Figure 2.6: Molecular structures of branched biligands 38 and 39 and biligand anchor 40. 
In the branched biligands 38 and 39, the 2° arm isolated through screens (in red) is linked by 
CuAAC chemistry to the monoligand anchor 37 (in blue). An alkyne is appended to the biligand 
39 to synthesize biligand anchor 40. The biotin tag spaced by a polyethylene glycol linker is 
utilized in assays and in the triligand screen. 
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2.3.2 Substitution of amino acid in linear ligand to developed branched 
biligand  
An alternative approach to develop a branched biligand would be through amino acid 
substitution of the developed linear ligand. For this strategy to succeed, one would need to 
replace amino acids in the linear biligand with an artificial amino acid with similar properties, so 
as to not disrupt the binding affinity of the ligand. To incorporate a reactive click handle in the 
reported linear biligand peptide to exploit branched peptides, we synthesized various artificial 
amino acids containing azide and alkynes in the side chain (Figure 2.7). Hydrophobicity of an 
amino acid is an important property that can be used to guide replacement of a component amino 
acid, with minimal disruption in binding properties22,23. The Relative Hydrophobicity Coefficient 
(RHC) is a measure of the hydrophobicity. The RHC values of the naturally occurring as well as 
the synthesized artificial amino acids were determined by modifying a literature method21.  In this 
method, the RHC of an amino acid X is proportional to the retention times of the peptide Ac-X-
GLF by HPLC. The RHC values of six of the synthesized amino acids are comparable to those of 
the hydrophobic naturally occuring amino acids, Leu, Ile, Phe and Trp.  Amino acid 21 has RHC 
value (2.21) lower than those of L-Tyr (17, RHC = 2.44) and L-Val (18, RHC = 2.61). So 21 can 
replace L-Tyr or L-Val within a peptide without a big change in hydrophobicity. Note that the 
same RHC values apply for replacing the D-amino acid with an artificial amino acid within a D-
peptide.  
For in situ click screens, this strategy was used to replace an amino acid of the D-anchor 
peptide with an artificial amino acid of similar hydrophobicity index (Figure 2.9). Starting with 
the earlier developed linear biligand 41 (Figure 2.9) we replaced D-Trp (RHC = 5.74) with the 
racemic artificial amino acid, Az5 (25, RHC = 6.50) to synthesize branched biligand 42.  
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The other strategy of amino acid replacement commonly followed in literature is to 
replace an amino acid with an artificial derivative having similar molecular structure. Following 
this strategy, D-phenylalanine of the biligand 41 was replaced with 4-azido-D-phenylalanine to 
synthesize biligand 43. The binding affinities of biligands 42 and 43 for bCAII as determined by 
SPR were similar to the binding affinity of linear biligand 41 for bCAII. So both replacement 
strategies do not compromise the binding affinity of the modified biligand in SPR measurements 
(Figure 2.10). However, the yield of 43 was not high due to instability of phenyl azide under the 
harsh deprotection conditions during peptide synthesis.  
 
Figure 2.7: Synthesized artificial amino acids with side chains containing azide or alkyne 
functional side chains. 
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Figure 2.8: Comparison of Relative Hydrophobicity Coefficients (RHC) of natural amio 
acids with those of synthesized artificial amino acids containing azide or alkyne functional 
group in the side chain. 
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Figure 2.9: Amino acid substitution in the linear biligand to develop branched biligands. 
The  linear biligand peptide 41 developed earlier is modified through amino acid substitutions to 
yield branched biligands 42 and 43. 
 
 
  
  
 
57 
 
Figure 2.10: SPR response sensograms of the branched biligands developed by amino acid 
substitution of the linear biligand.   
Sensograms of a) linear biligand 41 and branched biligands b) 42 and c) 43. The immobilization 
level of bCAII is 4000 RU. 
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2.3.3  Branched triligand development with substituted biligand 
The biligand 42 obtained by modifying the linear biligand 41 using the hydrophobicity 
approach was utilized as a new anchor peptide for a branched triligand peptide development. In 
the in situ click target screen, the Alexa Fluor 647 labeled bCAII pretreated with biligand 42 was 
screened against library D. The beads with high fluorescence intensity are automatically sorted 
using COPAS plus and sequenced by Maldi TOF/TOF24 (Table 2.6). The 8 most frequently 
occurring amino acids were used to generate the focused library. Screening this focused library 
gave highly homologous peptide sequences (Table 2.7). The hit sequences are found to contain 
into three motifs (denoted by red, green and blue colors in the sequences). One peptide was 
chosen from each of the three motifs as the triligand arm.  Triligand 45 was constructed with the 
sequence Ac-(D-Pra)fkifvr as the third peptide arm. Other two triligands 46 and 47 were 
synthesized with Ac-(D-Pra)irlflk and Ac-(D-Pra)kyffrf as the third peptide arm respectively. 
 
Figure 2.11: Schematic representation of the in situ click target screens TRI1 and TRI2 for 
developing branched triligand. 
The Alexa Fluor 647 (denoted by star) labeled bCAII protein is treated with biligand 42 and 
screened against on bead peptide library. 
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Figure 2.12: Branched triligand development through two generation target screen starting 
from a comprehensive randomized library. 
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Figure 2.13: Molecular structures of the linear triligand 44 and the three branched 
triligands 45, 46 and 47 obtained through the target screening process using modified 
biligand 42 and bovine carbonic anhydrase II protein. 
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2.3.4 Development of branched triligands using biligand anchor isolated 
through screens 
To select the best triligand binders for bCAII using biligand anchor 40 a product screen 
was performed. In the earlier target screens, beads with the high fluorescent intensity had been 
picked as hit beads. These beads contain peptide sequences that bind to the fluorescent protein. 
As the protein is pretreated with a high concentration of the anchor peptide, it is assumed that the 
hit sequences bind effectively to the protein in presence of a anchor peptide bound to the protein 
surface. An alternate method of screening is one that can directly detect the click product 
formation on the hit beads. This can be achieved by tagging the anchor peptide with the biotin tag 
and detecting the biotin rather than the protein. After the screen of the OBOC library with the 
mixture of the protein and the biotin labeled biligand anchor peptide 40, the protein and peptide 
binding nonspecifically to the beads are removed by harsh washes with denaturants like 
guanidium hydrochloride and dimethyl formamide. Only the anchor peptide covalently bound to 
the on bead peptide via triazole formation remain and are detected by an anti biotin antibody. To 
eliminate beads binding to the detection antibody, the beads are rescreened. The screen is 
identical to the first but uses biotin saturated anti biotin antibody for detection. The biotin 
containing beads remain colorless as the biotin binding site on the antibody is already occupied. 
The colorless hit beads were picked and sequenced. 
The four sequences obtained after the second screen are listed in Table 2.8. Note that the 
four sequences were obtained as the triligand arms starting from a randomized library containing 
~2 million unique sequences, while the sequences for the biligand were obtained from much 
smaller focused libraries. This process of direct detection of the clicked product is much more 
stringent than the earlier screen formats and do not need development and screening of 
consecutively focused libraries. The triligands 48, 49, 50 and 51 were synthesized by CuAAC 
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reaction of the biligand anchor with triligand arm Az4-hdtgf, Az4-hdtfy, Az4-hdegg and Az4-
ysqwa, respectively. 
Figure 2.14: Scheme for in situ click product screen TRI3 for development of branched 
triligand.  
The click product is directly detected on bead by detecting the biotin tag on the biligand anchor  
peptide. 
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Figure 2.15: Molecular structures of branched triligands developed through product screen 
against the bovine carbonic anhydrase II.  
The triligand arm (in green) is linked to the biligand anchor through CuAAC reaction. 
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2.3.5 Characteristics of developed capture agents 
The branched biligands and triligands developed were tested for their binding affinities, 
their selectivity and specificty for bCAII. The bovine and human carbonic anhydrase II have high 
homology in the amino acid sequence and protein structure and it had been noted that the 
monoligand and linear triligand had similar affinity for both. The same trend was observed for the 
ligands developed here. 
To demonstrate the efficiency of the ligands as detection agents they are used to detect 
bCAII spotted on a nitrocellulose membrane. The dot blot experiment is performed with a series 
of concentrations of the protein to determine the minimum amount of protein that can be detected 
(L.O.D). The L.O.D for the several triligands 45, 46 and 47 is 50 ng, as compared to 100 ng for 
the linear triligand 44. The L.O.Ds for all the ligands are noted in the Table 2.9. By nature, the 
dot blot experiments are dependent on the concentration of the detecting reagent. To cross verify 
the L.O.D.s for the ligands, two different concentrations of the ligands, 1 µM or 10 nM, are used 
in different sets of experiments. Although the values are different for the two sets of experiments, 
the same trend is observed relative to each other.  
The use of the developed ligands as capture agents is demonstrated in a series of 
sandwich ELISA assays. The biotinylated ligands were immobilized on a streptavidin plate and 
titrated with varying concentrations recombinant human carbonic anhydrase II. The absorbance at 
450nm wavelength was proportional to the binding of the capture agent to the protein and was 
used to calculate the relative affinity curves of the various ligands. 
The sandwich ELISA is a more sensitive assay than the dot blot and gives us better 
insight in the change in binding affinities. In the ELISA experiment we observe that when the D-
Trp in the linear biligand 41 was replaced by D,L-azidolysine to create the substituted branched 
biligand 42, there was a ~ 2 fold decrease in the binding affinity of the biligand for the protein, 
despite amino acid 25 and tryptophan having similar RHC values.  Thus substitution of an amino 
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acid in a linear ligand to make it branched did not make it a better binder in the biligand stage. 
However, when the substituted biligand 42 was used in the next phase of multiligand 
development process, the resultant triligand candidates 46 (EC50 50 nM) and 47 (EC50 58 nM) 
have ~3 times higher affinities than the earlier reported linear triligand 44 (EC50 144 nM). 
Figure 2.16: Biligands and triligands used as detection agents for bCAII.  
Dot blot using biligands for protein detection.  The picture on the left specifies the amount of 
bCAII protein spotted on the membrane.  
 
   
 
Table 2.9: Table summarizing the limits of detection (L.O.D) of the bovine carbonic 
anhydrase II protein using the developed multiligands as detection agents. 
 
Ligand L.O.D. using 10 nM ligand 
solution for detection (ng) 
L.O.D. using 1 uM ligand 
solution for detection (ng) 
Linear biligand 41 200  Not determined 
Branched biligand 42  300  Not determined 
Linear triligand 44 100  Not determined 
Branched triligand 45 50  50 ng 
Branched triligand 46 100  50 ng 
Branched triligand 47 50  50 ng 
Branched triligand 48 200  50 ng 
Branched triligand 49 200  50 ng 
Branched triligand 50 200  50 ng 
Branched triligand 51 200  50 ng 
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Figure 2.17: ELISA demonstrating relative binding affinities of biligands  and triligands. 
Binding of linear biligand 41 (purple), branched biligand 42 (black), linear triligand 44 (red), and 
branched triligands 46 (blue) and 47 (green) for the CAII protein. The biotinylated ligands are 
immobilized on a SA plate and treated with different concentrations of the protein. The individual 
absorbance values are denoted as points and the fits are denoted as solid lines.  
 
 
 
2.3.6 Substitution of triazole linkage by triazole mimic 
The orientation of the alkyne and azide during in situ protein catalyzed click chemistry 
dictates the nature of the triazole linkage between the two functionalities. If the protein scaffolds 
and orients the azide and alkyne is a syn orientation, a 1,5 - disubstituted triazole linkage is 
formed by the in situ click reaction. If, on the other hand, the protein scaffolds and orients the 
azide and alkyne is an anti orientation, a 1,4 - disubstituted triazole linkage is formed by the in 
situ click reaction. A protein, when catalyzing the click reaction, may yield only one triazole 
product exclusively. So it is important to check both the triazole products for binding affinity to 
the protein. While the 1,4 substituted triazole linked peptide biligand can be synthesized 
relatively simply by copper-catalyzed alkyne azide chemistry (CUAAC), it is synthetically 
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challenging to synthesize the 1,5 disubstituted triazole linked peptide biligand in bulk for 
different assays. To overcome this difficulty, a mimic of the 1,5 disubstituted triazole linker was 
synthesized. As proline has been successfully replaced by the 1,5 disubstituted triazole molecule 
in proteins25, we reversed the concept to replace 1,5 disubstituted triazole with proline.  To 
recreate the length of the 1,5-triazole link that is formed between L-azidolysine and D-propargyl 
glycine, as in the in situ protein click reaction, D-Pro and D-Asp was coupled to the acid side 
chain of L-diaminobutyric acid.  
For evaluating the binding affinity of the 1,5-triazole containing ligands as compared to 
the 1,4-triazole containing ligands for the protein, two branched biligands 38 and 39 were 
synthesized containing the 1,5-triazole mimic linker. Each of the ligands were immobilized on an 
ELISA platform and titrated with the protein. For both the branched triligands 38 and 39, the 1,5-
triazole mimic linked ligands have higher affinities for the CAII than the corresponding 1,4 
triazole linked ligands. The binding affinity of the 1,5 triazole mimic linked biligand was ~3.3 
times the binding affinity of the 1,4 triaozle linked ligand 38.  The binding affinity of the 1,5-
triazole mimic linked biligand for protein CAII was ~3 times that for 1,4 triazole linked branched 
biligand 39. This indicates that at the biligand stage, the protein catalyzes the formation of the 1,5 
triazole linked biligand, where the two peptide arms are turned towards each other rather than the 
1,4 triazole linked biligand, where the two peptide arms are placed away from each other. 
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Figure 2.18: Molecular structure comparison of 1,5 disubstituted triazole linked biligand 
and its mimic. 
A dipeptide D-Pro-D-Asp is coupled to the side chain of L-diaminobutyric acid to mimic the 1,5 
triazole linker. The number of atoms in the linker and the orientation of the triazole are 
maintained. The two peptide arms are syn to each other in the 1,5 mimic.  
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Figure 2.19: Comparison of the binding affinities of 1,4 and 1,5 disubstituted regioisomers 
of biligands to carbonic anhydrase II protein. 
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2.4 Conclusions 
In this work we evaluate the effect of branching a linear peptide ligand starting with the 
same weak binding monoligand peptide arm. Two approaches are described. One involves 
replacing an amino acid in the isolated linear biligand with an amino acid of similar 
hydrophobicity, to make the biligand branched. The protein, in presence of this branched biligand 
searches for a third linear peptide arm. The resulting triligands developed are branched. The 
developed triligands ligands 45, 46 and 47 have either similar or lower limits of detection than the 
linear triligand previously developed.  The other strategy involves using an OBOC peptide library 
with random number and position of the branching amino acid azidolysine to find the natural 
preference of the protein binding in presence of the weak monoligand peptide. Using focused 
libraries, this pattern is further resolved as wX(Az4)xw or vX(Az4)Xw. The protein in presence 
of this branched biligand anchor is screened against a linear peptide library to find triligand 
binders. Of the four ligands isolated though the screens, two triligand arms are found to have a 
pattern of hdtXX. However despite the high homology of the triligand sequences, their limit of 
detection are higher than the other branched triligands using the semi quantitative dot blot 
method. The ligands are also used as capture agents in an ELISA platform. The ELISA assays 
show the same trend as the dot blots, with branched triligands 46 and 47 having ~3 times higher 
affinity than the linear triligand 44.  
While the protein might form the 1,4 or 1,5 triazole linkage between the two peptides, 
where the relative peptide orientations are very different, bulk synthesis and characterizations of 
ligands are performed with 1,4 triazole linked peptide ligands. Here we determine whether 
selecting a particular regioisomer for further screens can lead to a change in binding affinity. To 
circumvent the difficult synthesis of the 1,5 triazole linked peptide, a mimicking strategy is 
applied that conserves the linker length and triazole cis or trans orientation.  All the biligands are 
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found to favor the triazole cis orientation, particularly the branched biligands developed through 
screening. This might partially explain why we do not attain the desired affinity of the PCC agent 
in the triligand stage, as we screened with the 1,4 diastereomer of the biligand with low affinity. 
In the triligand stage also the 1,5 regioisomers might have better affinities than the 1,4 
regioisomers. In the development of future PCC agents, it would be beneficial to check the 
binding affinity of the different regioisomers of the multiligand from the biligand stage and 
choose the best binder before proceding to triligand development.  
 
 
  
  
 
72 
 
REFERENCES: 
 
 (1) Binz, H. K.; Amstutz, P.; Kohl, A.; Stumpp, M. T.; Briand, C.; Forrer, P.; 
Grutter, M. G.; Pluckthun, A. Nature Biotechnology 2004, 22, 575. 
 (2) Hey, T.; Fiedler, E.; Rudolph, R.; Fiedler, M. Trends Biotechnol 2005, 23, 514. 
 (3) Ladner, R. C.; Sato, A. K.; Gorzelany, J.; de Souza, M. Drug Discovery Today 
2004, 9, 525. 
 (4) Smith, G. P.; Petrenko, V. A. Chem Rev 1997, 97, 391. 
 (5) Strehlitz, B.; Nikolaus, N.; Stoltenburg, R. Sensors 2008, 8, 4296. 
 (6) Holliger, P.; Hudson, P. J. Nature Biotechnology 2005, 23, 1126. 
 (7) Desmyter, A.; Decanniere, K.; Muyldermans, S.; Wyns, L. J Biol Chem 2001, 
276, 26285. 
 (8) Cox, J. C.; Hayhurst, A.; Hesselberth, J.; Bayer, T. S.; Georgiou, G.; Ellington, 
A. D. Nucleic Acids Res 2002, 30. 
 (9) McCauley, T. G.; Hamaguchi, N.; Stanton, M. Anal Biochem 2003, 319, 244. 
 (10) Kehoe, J. W.; Kay, B. K. Chemical Reviews 2005, 105, 4056. 
 (11) Brody, E. N.; Gold, L. J Biotechnol 2000, 74. 
 (12) Agnew, H. D.; Rohde, R. D.; Millward, S. W.; Nag, A.; Yeo, W.-S.; Hein, J. E.; 
Pitram, S. M.; Tariq, A. A.; Burns, V. M.; Krom, R. J.; Fokin, V. V.; Sharpless, K. B.; Heath, J. 
R. Angewandte Chemie-International Edition 2009, 48, 4944. 
 (13) Doig, A. J.; Sternberg, M. J. Protein Sci 1995, 4, 2247. 
 (14) Falciani, C.; Lozzi, L.; Pini, A.; Corti, F.; Fabbrini, M.; Bernini, A.; Lelli, B.; 
Niccolai, N.; Bracci, L. Chem Biol Drug Des 2007, 69, 216. 
 (15) Bohrsch, V.; Mathew, T.; Zieringer, M.; Vallee, M. R.; Artner, L. M.; Dernedde, 
J.; Haag, R.; Hackenberger, C. P. Org Biomol Chem 2012, 10, 6211. 
 (16) Le Chevalier Isaad, A.; Papini, A. M.; Chorev, M.; Rovero, P. J Pept Sci 2009, 
15, 451. 
 (17) Sun, D.; Jones, V.; Carson, E. I.; Lee, R. E.; Scherman, M. S.; McNeil, M. R.; 
Lee, R. E. Bioorg Med Chem Lett 2007, 17, 6899. 
 (18) Wilkinson, B. L.; Bornaghi, L. F.; Houston, T. A.; Innocenti, A.; Supuran, C. T.; 
Poulsen, S.-A. J Med Chem 2006, 49, 6539. 
 (19) Chenault, H. K., Dahmer, J., Whitesides, G.M. J. Am. Chem. Soc. 1989, 111, 
6354. 
 (20) Fields, G. B.; Noble, R. L. International Journal of Peptide and Protein 
Research 1990, 35, 161. 
 (21) Kovacs, J. M.; Mant, C. T.; Hodges, R. S. Biopolymers 2006, 84, 283. 
 (22) Kiyota, T.; Lee, S.; Sugihara, G. Biochemistry 1996, 35, 13196. 
 (23) Wieprecht, T.; Dathe, M.; Beyermann, M.; Krause, E.; Maloy, W. L.; 
MacDonald, D. L.; Bienert, M. Biochemistry 1997, 36, 6124. 
 (24) Franz, A. H.; Liu, R.; Song, A.; Lam, K. S.; Lebrilla, C. B. Journal of 
Combinatorial Chemistry 2003, 5, 125. 
 (25) Tam, A.; Arnold, U.; Soellner, M. B.; Raines, R. T. Journal of the American 
Chemical Society 2007, 129, 12670. 
 
 
  
 
73 
 
Chapter  3: Epitope targeting strategy: developing capture agents 
targeted against C terminal hydrophobic motif of the Akt2 protein 
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3.1 Introduction  
 
The term epitope targeting is widely referred to in antibody development literature. An 
epitope is a part of an antigen that is recognized by the immune system, specifically by 
antibodies, T cells and B cells. An epitope can be a continuous or discontinuous stretch of amino 
acids within the antigen1. The ability of the antibodies to specifically target one vital region 
(generally ~10 amino acids) within a protein is its major advantage, as in most of todays 
biological analytic and diagnostic platforms, it is not only sufficient to recognize a protein, but it 
is vital to identify certain states or mutations of the protein (e.g. phosphorylation of a certain 
residue2 or the point mutation of an amino acid3). In this chapter, we describe the development of 
a peptide based capture agent to specifically target a certain region of the protein. This strategy 
will henceforth be referred to as the epitope targeting strategy, the epitope being, in this case, a 
continuous region of the protein. In this strategy, the target protein region is chemically 
synthesized as a peptide so that it can be modified to incorporate an azide/alkyne handle. The 
peptide not only acts as the catalyst, but also as reaction component when screened against a 
peptide library that contains the complementary click handle. For the peptide that binds in proper 
region and in proper orientation, the weak peptide peptide interaction is strengthened by the 
covalent bond formation between the azide and alkyne functionalities. Once the peptide binder to 
the target peptide is identified, the screening process is repeated to develop a biligand and finally 
a triligand. In the multiligand screens, the entire protein is used as the target.  
The peptide target is a 32mer peptide fragment from the C terminal of Akt2. There were 
several reasons for choosing this target. This peptide region is flexible and unstructured, so that 
its tertiary structure is not resolved in solved crystal structures of Akt2. It is likely that this 
peptide fragment is on the surface of the protein and not buried inside the protein. Since the target 
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is only a portion of the protein rather than the entire protein, to make the strategy successful, the 
target peptide should obey two criteria: firstly, it should be surface exposed on the entire protein 
and secondly, the properties of the flexible modified target peptide should not be significantly 
different from the peptide fragment in the entire protein.  This target peptide satisfied all the 
structural criteria.  
The selected target fragment was also selected on the basis of its functional significance, 
as it is the site of a serine phosphorylation and contains a hydrophobic motif that acts as an 
allosteric activator of the Akt2 protein. Akt collectively refers to three isoforms (Akt1, Akt2, and 
Akt3), and is a member of the serine/threonine AGC protein kinase family4,5. Akt plays a central 
regulatory role in growth factor signaling, and serves as a key node in the phosphatidylinositol 3-
kinase (PI3k) signaling pathway. Over expression and/or hyperactivation of Akt is associated 
with breast6, ovarian7, colon8, pancreatic9, and bile duct10 cancers, making Akt an attractive drug 
and diagnostic target11. Ser474 is located in the hydrophobic motif (HM) of the C-terminal tail, 
and is phosphorylated by mTOR Rictor12. The phosphorylated HM acts as an allosteric activator 
of Akt2 by binding to a hydrophobic groove in the N-lobe of Akt2 and enhancing the kinase 
activity 10-fold13,14.  In the context of current studies showing that ATP competitive inhibitors of 
Akt2 can cause hyperphosphorylation of the protein15,16, it can be worthwhile to find binders to 
the C terminal kinase regulatory domain, as such binders would have a high potential to regulate 
kinase activity. 
Initially we explored two alternative methods of modifying the target peptide with a click 
handle. The azide group provides an anchor site for an in situ click reaction17,18 while the biotin 
label is used as a screening and assay handle. In the first method, the 32-mer C-terminal 
polypeptide fragment of Akt2 (amino acids 450-481) with the phosphorylated Serine 474 (p-
S474) is modified with a dinuclear Zn (II) DPA type complex, which has an appended biotin 
label and an azide handle. The dinuclear Zn(II)DPA selectively binds to the phosphate anion19 
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and provides an initial in situ click reaction site adjacent to the phosphorylated residue azide 
functionality close to the hydrophobic motif. In the second method, the azide handle is 
incorporated inside the 32mer C terminal polypeptide fragment with pSer474, by substituting an 
amino acid within the peptide. The hydrophobic motif FPQF(pS)YS is left unperturbed and  I479, 
separated by two amino acids from the hydrophobic motif, is replaced by L-azidolysine. 
However, as screens in both methods yield very similar ligands, we pursue only the first method. 
The monoligand obtained from the first method is expanded through further screens against the 
peptide and protein to develop several biligands and ultimately two triligands. In this chapter, I 
describe the process of epitope targeting and the development of triligand peptides. In the next 
chapter, the developed multiligands are characterized and their effects on the kinase activity of 
the Akt2 protein are explored. 
3.2 Materials and methods 
3.2.1  Materials  
Fmoc amino acids were purchased from Anaspec (San Jose, CA) and AAPPTec 
(Louisville, KY) and used as received.  TentaGel S-NH2 resin (diameter 90 µm, capacity 0.28 
mmol/g) was obtained from Anaspec (San Jose, CA) and utilized for OBOC library construction. 
Biotin NovaTag™ resin, Biotin – PEG NovaTag™ resin, Fmoc – NH - (PEG)2 -OH (13 atoms) 
were obtained from EMD Chemicals, Inc. (Gibbstown, NJ) and used for synthesis of biotinylated 
peptides. Amide Sieber resin (capacity 0.3-0.6 mmol/g) purchased from Anaspec (San Jose, CA) 
was used for synthesis of protected peptides. NMP (1-methyl-2 -pyrrolidinone), HATU ((2-(7-
Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylammonium hexafluorophosphate) and DIEA 
(N,N′-diisopropylethylamine) used in peptide synthesis were bought from EMD Chemicals, Inc. 
(Gibbstown, NJ), ChemPep (Miami, FL), and Sigma-Aldrich (St. Louis, MO) respectively. DMF 
(N, N′-dimethylformamide), piperidine, TFA (trifluoroacetic acid, 98% min. titration), and TES 
(triethylsilane) were purchased from Sigma-Aldrich (St. Louis, MO). 5-Azido-pentanoic acid was 
  
 
77 
purchased from Bachem Americas, Inc. (Torrance, CA). BCIP (5-Bromo-4-chloro-3-indolyl 
phosphate) was purchased from Promega. Active Akt2 (with N terminal His6 tag) was purchased 
from Abcam (Cambridge, MA). Mouse anti biotin antibody-Alkaline Phosphatase conjugate was 
purchased from Sigma Aldrich.  
3.2.2 Methods 
3.2.2.1 Synthesis of phosphate binding dinuclear metal ligand complex 
3,5-bis((bis(pyridin-2 -ylmethyl)amino)methyl)-4-hydroxybenzoic acid ester (Compound 1): 
N, N–di(2-picolyl) amine (2.50 g, 12.5 mmol) in ethanol/water/HCl (30 mL/90 mL/0.6 mL of 2M 
) was added to paraben ( 830 mg, 5 mmol) and paraformaldehyde ( 475 mg, 15.67 mmol). The 
mixture was heated under reflux for 3 days and then allowed to cool to room temperature20,21. 
Then dicholromethane (300 mL) and water (100 mL) was added to the reaction mixture and a 
liquid phase extraction was done.  The organic phase, containing the compound, was washed 
once with 300 mL of water and dried over anhydrous sodium sulphate. A yellowish gummy 
semisolid was obtained after evaporation of solvent. Column chromatography on silica gel with 
eluents dicholoromethane /methanol /ammonium hydroxide afforded light yellow semi solid. 
Calculated mass: [M+H] 588.6 Observed mass: [M+H] 589.29  
3,5-bis((bis(pyridin-2-ylmethyl)amino)methyl)-4-hydroxybenzoic acid (Compound 2):  The 
purified semisolid compound 2 was dissolved in 2 M NaOH in 1:1 ethanol/water solution and 
stirred at 60 °C for 2 days. Then the solution was neutralized by concentrated hydrochloric acid.  
The compound was extracted with methanol and used in further synthesis. Calculated mass: 
[M+H]+ 561.25, [M-H]- 559.25 Observed mass: [M+H]+ 561.25, [M-H]- 559.4  
Zn2L-Az4-PEG2-Biotin: D,L-Fmoc-azidolysine was coupled to Biotin-PEG NovaTag resin  
(coupling efficiency 0.48 mmole/g) following standard Fmoc solid phase synthesis protocol. The 
Nα-Fmoc protecting group was removed by treating with 20% piperidine in NMP. 1.5 equivalents 
of compound 2 were coupled overnight to the resin. The molecule was cleaved off the resin using 
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a cocktail of TFA, TES and double distilled water (95:2.5:2.5), precipitated in ice cold ether and 
lyophilized. The crude solid was used in further synthesis. 2 equivalents of zinc acetate was 
dissolved in methanol and added to 1 equivalent of compound 2 and stirred overnight at room 
temperature. The solvent was removed under reduced pressure and the solid was purified using a 
gradient of water and acetonitrile and 0.1% TFA on the RP-HPLC (Beckman Coulter System 
Gold 126 Solvent Module and 168 Detector) using a C18 reversed phase semi-preparative 
column (Phenomenex Luna 10 µm, 250 × 10 mm). Calculated mass: [M].2H2O 1369.45, 
Observed mass: [M].2H2O 1369. 
3.2.2.2 Verification of binding of Zn2L-Az4-PEG2-Biotin to phospho-amino acids and a 
phosphate containing peptide  
422 µM solution of Zn2L-Az4-PEG2-Biotin was made dissolving the HPLC purified solid 
in 10 mM tris borate buffer (TBS) (pH 8). Saturated solutions of pure phosphoserine, 
phosphotyrosine and pSrc substrate Ac-I-pY-GEF (Novabiochem) was made in the buffer. The 
Zn2L-Az4-PEG2-Biotin solution was added to either of the saturated solutions in a 1:1 ratio. A 
fresh matrix was prepared by dissolving 2,4,6-trihydroxyacetophenone (THAP) in 10 mM tris 
borate buffer (pH 8) with 50% acetonitrile (20 mg/ml). Each solution mixed in a 1:1 ratio with the 
matrix, and subjected to Maldi TOF in a positive mode, show the peaks corresponding to (Zn2L-
Az4-PEG2-Biotin – pSer), (Zn2L-Az4-PEG2-Biotin – pTyr) and (Zn2L-Az4-PEG2-Biotin – Ac-I-
pY-GEF)22. The pure compound Zn2L-Az4-PEG2-Biotin mixed with the THAP matrix yields the 
major peak corresponding to its mass.  
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Figure 3.1: Synthesis of dinuclear Zn chelator Zn2L-Az4-PEG2-Biotin. 
Starting from paraben, 3,5-bis((bis(pyridin-2-ylmethyl)amino)methyl)-4-hydroxybenzoic acid is 
synthesized (compound 2). Compound 2 is coupled via amide coupling to PEG containing biotin 
novatag resin. The compound cleaved off bead and treated with Zn acetate yields Zn2L-Az4-
PEG2-Biotin. 
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Figure 3.2: Evidence of binding of dinuclear zinc chelator to phospho amino acids and 
phospho peptide. 
Structure and Maldi TOF spectra of the Zn chelator Zn2L-Az4-PEG2-Biotin and complexes of 
Zn2L-Az4-PEG2-Biotin with phosphorylated amino acids and phosphorylated peptides. Mass 
spectrum of a) pure Zn2L-Az4-PEG2-Biotin (observed mass M.2H2O = 1369, (M-N2).2H2O = 
1343.8 ; expected mass M.2H2O = 1369.45, (M-N2).2H2O = 1343.45). b) Zn2L-Az4-PEG2-Biotin 
- phospho-serine (observed mass =1454.4;  expected mass = 1454.43) c) Zn2L-Az4-PEG2-Biotin - 
phospho-tyrosine (observed mass = 1532.39 ; expected mass = 1532.46). d. Mass spectrum and 
structure of Zn2L-Az4-PEG2-Biotin - Ac-I-pY-GEF (observed mass =2019.57; expected mass = 
2019.86).  
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3.2.2.3 Peptide library Synthesis   
Randomized OBOC23 libraries of hexapeptides were synthesized using the Titan 357 
Automated Peptide Synthesizer (AAPPTec) on 90 µm polyethylene glycol-grafted polystyrene 
beads (TentaGel S-NH2, 0.28 mmol/g, 2.86 x 106 beads/g). All the libraries used unnatural D 
amino acids including Fmoc-D-propargylglycine.  In library C, for azide incorporation, Fmoc-L-
azido lysine (Anaspec) was coupled to the N termini of the on bead peptides. All the libraries 
contained 10% D-Methionine at the C terminal, for compatibility with Maldi-TOF/ TOF 
sequencing. The 10% Methionine was incorporated following literature protocol24. 
 
Table 3.1: Summary of libraries used in screens against the Akt2 protein. 
 
Formula Components Number of unique sequences 
Library A: D-Pra-XXXXX-
10% M-TG 
X = 18 D amino acids except 
D-Met and D-Cys 
1,889,568 
Library B: XXXXX -D-Pra-
10%M-TG 
X = 18 D amino acids except 
D-Met and D-Cys 
1,889,568 
Library C: Az4- XXXXX -
10%M-TG 
X = 18 D amino acids except 
D-Met and D-Cys 
1,889,568 
 
3.2.2.4 Screening with One Bead One Compound (OBOC) peptide library 
Screen for mono-L:  
50 nM solution of target phospho-peptide was made by diluting 0.5mg/ml DMSO stock 
in 25 mM tris chloride, 150 mM NaCl, 2 mM KCl, pH 8) (TBS). 100 µM solution of the metal 
chelated anchor Zn2L-Az4-PEG2-Biotin was added to the 50 nM solution of the phosphor-peptide-
1 and shaken overnight at room temperature. Before the addition to the OBOC library, Bovine 
Serum Albumin (BSA) and Tween 20 was added to the solution to make the final concentrations 
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0.1 % BSA and 0.05% tween 20 in the buffer. The screen was conducted using library A, of the 
form D-Pra-XXXXX-10% M-TG. 250 mg of beads were used in the screen. The beads were 
equilibrated in binding buffer (25 mM tris hydrochloride pH 7.5, 150 mM NaCl, 0.1% BSA, 
0.05% Tween 20) by shaking for 8 hours. The complex formed by incubating the target phospho-
peptide with Zn2L-Az4-PEG2-Biotin, denoted as Complex-1, was added to the swelled beads and 
shaken overnight at room temperature. The beads were washed three times with the binding 
buffer. A 1:10,000 dilution of mouse anti biotin monoclonal antibody-Alkaline Phosphatase 
conjugate (Sigma) in binding buffer was added to the beads. The beads were then washed three 
times with binding buffer, thrice with TBST (0.05% tween 20/TBS) and three times with TBS. 
 A BCIP solution was freshly prepared by adding 33 ul of BCIP (50 mg/ml) stock solution in 10 
ml of Alkaline Phosphatase buffer (100 mM Tris-HCl, pH 9.0, 150 mM NaCl, 1 mM MgCl2) 
(Promega). The beads were washed once with the Alkaline Phosphatase buffer, and then treated 
with the fresh BCIP solution. The hit beads turned turquoise blue due to a colorimetric reaction of 
Alkaline Phosphatase with BCIP.  The reaction was quenched after one hour with 0.1 N HCl 
solution. The hit beads were picked with a pipette tip and transferred to a spinnex tube. The 
turquoise color of the hit beads was removed by washing with DMF. The proteins on the beads 
were stripped buffer. The exact screen protocol was repeated, this time using a preincubated 
mixture of 2.5 mM biotin and 1:10,000 dilution of a mouse anti biotin monoclonal-Alkaline 
Phosphatase conjugate (Sigma) as the secondary antibody. On addition of the BCIP, the true hits, 
due to competition with biotin, remain clear. The clear beads were manually picked, washed with 
7.5 M guanidium hydrochloride (pH 2) and water, and sequenced using the Edman Sequencer. 
 
Table 3.2: Sequences of hits from the monoligand (mono-L) screen. 
 
D-Pra X1 X2 X3 X4 X5 
D-Pra w k v k l 
D-Pra w k v k l 
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Screen for bi-L: 
Prescreen:  
2 batches of 135 mg of library B of form XXXXX-D-Pra- 10% M- TG were washed in 
water, and swelled overnight in binding buffer. 20 µM and 50 µM solutions of compound 4 was 
added to the beads and shaken for 10 hours at room temperature. The beads were washed thrice, 
for fifteen minutes, with the binding buffer.  A 1:10,000 dilution of mouse anti biotin antibody-
Alkaline phosphatase conjugate (Sigma) in binding buffer was added to the beads. The beads 
were washed three times, for fifteen minutes each, with wash buffer 1, wash buffer 2, TBS and 
then washed once with AP buffer. The beads were then developed in BCIP solution for 35 
minutes and quenched with 0.1 N HCl.  The blue hit beads, which were background binders to the 
compound 4 or the detection antibody, were picked up manually. The clear beads were stringently 
washed with DMF, guanidium hydrochloride and water as described in the previous paragraph. 
Product screen: 
  The washed beads from each prescreen were dried, then swelled overnight in binding in 8 
ml fritted polypropylene solid-phase synthesis tubes.  In two separate eppendorf tubes, 20 µM 
and 50 µM solution of compound 4 was incubated overnight at room temperature with 10 nM and 
25 nM target phospho-peptide solution, respectively, in binding buffer. 4 mL of each of the two 
solutions were added to a precleared swelled bead batch and the tubes were shaken at room 
temperature for ten hours. The beads were washed three times, for fifteen minutes each, with 
wash buffer 1 followed by three fifteen minute washes with wash buffer 2. The beads are then 
developed in BCIP solution for thirty-five minutes and quenched with 0.1 N HCl. The blue hit 
beads were picked up manually, stringently washed with DMF, guanidium hydrochloride and 
water, and sequenced on the Edman Sequencer.  The sequences from the biligand screen are 
given in Table 3.3 and Table 3.4.  
 
  
 
84 
Table 3.3: Hit sequences from the biligand (bi-L) screen with 25 nM target peptide. 
 
X1 X2 X3 X4 X5      D-Pra 
h n G i i D-Pra 
h n G r e D-Pra 
h r y y G D-Pra 
v n r r f D-Pra 
h n G G d D-Pra 
a y p h f D-Pra 
G f r r f D-Pra 
r G f f l D-Pra 
h n G y G D-Pra 
 
 
Table 3.4 Hit sequences for biligand screen with 10 nM target peptide.  
 
 
 
 
 
 
 
 
 
 
X1 X2 X3 X4 X5 D-Pra 
v y y r h D-Pra 
h n G a I D-Pra 
f h y y y D-Pra 
f y h k h D-Pra 
p f q h f D-Pra 
s h f y t D-Pra 
v h G a a D-Pra 
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Screen for N-term-tri-L: 
Prescreen:  
500 mg of library A of the form D-Pra-XXXXX-10%M- TG were swelled in binding 
buffer 2 overnight.  The beads were incubated with 25 µM solution of Anchor-3N (Figure 3.10) in 
binding buffer for two hours at 4°C. The beads were washed three times for five minutes each, 
with binding buffer. The beads were treated for two hours with 7.5 M Guanidium chloride (pH = 
2) and washed ten times with double distilled water. The beads were reequilibrated in binding 
buffer.  A 1:10,000 dilution of mouse anti biotin antibody-Alkaline phosphatase conjugate 
(Sigma) in binding buffer was added to the beads. The beads were washed three times, for five 
minutes each, with wash buffer 3  (25 mM Tris-Cl (pH = 7.5), 150 mM NaCl, 10 mM MgCl2,  
0 . 0 5 % (v/v) Tween-20), followed by three five minute washes with wash buffer 4 (25 mM 
Tris-Cl (pH = 7.5), 150 mM NaCl, 10 mM MgCl2). The beads were then developed in BCIP 
solution for thirty minutes and quenched with 0.1 N HCl.  The blue hit beads, which were 
background binders to the Anchor-3N or the antibody were separated from the rest of the beads.  
The clear beads were stringently washed with DMF, guanidium hydrochloride and water and used 
in the product screen. 
Product screen:  
The clear beads from the preclear screen were swelled overnight in binding buffer 2. 25 
µM solution of biligand anchor was incubated for 30 minutes at 4°C with 50 nM Akt2 in binding 
buffer. The solution was added to the beads and shaken at 4°C for two hours. The beads were 
washed three times, for five minutes each, with the binding buffer. The beads were treated for 
two hours with 7.5 mM Guanidium chloride (pH = 2) and washed ten times with double distilled 
water. The beads were reequilibrated in binding buffer.  A 1:10,000 dilution of mouse anti biotin 
antibody-Alkaline phosphatase conjugate (Sigma) in binding buffer was added to the beads. The 
beads were washed three times, for five minutes each, with wash buffer 3 followed by three five 
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minutes washes with wash buffer 4. The beads were then developed in BCIP solution for thirty 
minutes and quenched with 0.1 N HCl. The blue hit beads were picked up manually, stringently 
washed with DMF, guanidium hydrochloride and water, and used in the target screen. 
Target screen:  
The washed hit beads from the product screen were swelled overnight in binding buffer 2 
(50 nM Akt2 protein, preincubated with 73.5 µM biligand anchor for thirty minutes at 4°C, was 
added to the swelled beads and the beads were shaken for ninety minutes at 4°C. The beads were 
washed three times, for five minutes each, with binding buffer 2.  A 1:1000 dilution of mouse anti 
His6 antibody (Abcam) in binding buffer was added to the beads and incubated for an hour with 
shaking at 4°C. Following three five minute washes with the binding buffer, a 1:10,000 diluted 
solution of anti mouse –alkaline phosphatase (Sigma) was added and the shaken for one hour at 
4°C. The beads were washed three times for five minutes each with wash buffer 3, followed by 
three five minute washes with wash buffer 4. The beads were then developed in BCIP solution 
for thirty minutes and quenched with 0.1 N HCl. The blue hit beads were picked up manually, 
stringently washed with DMF, guanidium hydrochloride and water, and sequenced on the Edman 
Sequencer. The sequences obtained are listed in Table 3.5. Because of poor resolution of amino 
acid standards in the Edman Peptide Sequencer during that time, some peptides were assigned to 
have either one of two amino acids in some positions. 
Elimination of peptides binding to anti-Akt antibody:  
Since a preclear screen was not performed against the mouse-Anti His6 antibody and the 
anti-mouse-alkaline phosphatase antibody, to eliminate peptide binders to the antibodies, all the 
dark colored peptide hits obtained in the earlier target screen were synthesized on Tentagel-S-
NH2 resin. 10 beads of each sequence was taken in spinnex tubes, equilibrated in binding buffer, 
and then treated with a 1:1000 diluted solution of mouse anti His6 antibody (Abcam) for an hour 
at 4°C. Following three five minute washes with the binding buffer, a 1:10,000 diluted solution of 
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anti mouse –alkaline phosphatase was added and the shaken for one hour at 4°C. The beads were 
washed three times for five minutes each with wash buffer 3, followed by three five minute 
washes with wash buffer 4. The beads were then developed in BCIP solution for thirty minutes 
and quenched with 0.1 N HCl. The color intensity of the different sequences was recorded in 
Table 3.6, along with the probability that the sequence is a binder to the protein and not a 
background binder (clear beads).  The probability arises from the poor resolution of certain amino 
acid standards in the Edman sequencer during sequencing the hits from the N terminal triligand 
target screen. 
 
Table 3.5:  Hit sequences for N terminal triligand (N-term-tri-L) screen. 
 
D-Pra X1 X2 X3 X4 X5 
D-Pra k/l* f q f r 
D-Pra r d/n* r f r 
D-Pra y v y r f 
D-Pra s s G r y 
D-Pra y y r f g 
D-Pra s f r r f 
D-Pra s v r f r 
D-Pra i k/l* r r a 
D-Pra r q/t* k/l* w r 
D-Pra r q/t* s r r 
D-Pra r r i y y 
D-Pra r f G r q/t* 
∗Alternative amino acid signals from poor resolution of the amino acid 
 standards of the Edman sequencing machine. 
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Table 3.6: Elimination of peptide binders to the detection antibody for the N terminal 
triligand (N-term-tri-L) screen. 
 
D-Pra X1 X2 X3 X4 X5 Color 
Probability of  
being 
right sequence 
D-Pra k f q f r light 0.25 
D-Pra l f q f r light 0.25 
D-Pra k f t f r light 0.25 
D-Pra l f t f r light 0.25 
D-Pra r d r f r No color 0.5 
D-Pra r n r f r medium 0.5 
D-Pra y v y r f light 1 
D-Pra s s g r y No color 1 
D-Pra r r i y y dark 1 
D-Pra y y r f G No color 1 
D-Pra s f r r f light 1 
 
Screen for C-term-tri-L: 
Prescreen:  
500 mgs of library C of form H2N-Az4-XXXXX-10%M-TG was swelled in binding 
buffer 2 overnight.  The beads were incubated with 100 µM solution of Anchor-3C in binding 
buffer for two hours at 4°C. The same screening protocol as for the prescreen for N-term-Tri-L 
screen is followed. The blue hit beads, which were background binders to the Anchor-3C or the 
detection antibody were separated from the rest of the beads. The clear beads were stringently 
washed with DMF, guanidium hydrochloride and water and used in the product screen that 
followed. 
Product screen: 
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The washed beads from the prescreen were swelled overnight in binding buffer 2. 100 
uM solution of Anchor-3C was incubated for thirty minutes at 4°C with 50 nM Akt2 in binding 
buffer. The same screening protocol as for the product screen for N-term-Tri-L is followed. The 
sequences are recorded in Table 3.7. 
 
Table 3.7: Hit sequences from the C terminal triligand (C-term-tri-L) screen. 
 
L-Az4 X1 X2 X3 X4 X5 
L-Az4 h d G s q 
L-Az4 h d G w w 
L-AZ4 h d G i v 
L-Az4 h d G d w 
L-Az4 h d G G - * 
L-Az4 h d G d r 
L-Az4 h d G G f 
L-Az4 h d G G e 
L-Az4 h d G s f 
L-Az4 h d G q k 
L-Az4 h d G s a 
L-Az4 h d G k f 
L-Az4 r l e a v 
 
3.2.2.5  Bulk peptide synthesis 
Fully deprotected peptides were synthesized on Rink Amide MBHA resin. Biotinylated 
peptides were synthesized on Biotin Novatag resin. Polyethylene glycol linker between the biotin 
tag and the amino acids were achieved by coupling Fmoc-PEG2-COOH (13 atoms) directly to the 
Biotin Novatag resin before coupling other amino acids. Side chain protected peptides used in 
certain steps of synthesis were synthesized on Sieber Amide resin. Fmoc-Ser(OPO3Bzl)-OH 
(AAPPTec) was used for the incorporation of phosphoserine in the phosphorylated peptides.  
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Peptides generally were synthesized on the Titan 357 Automatic Peptide Synthesizer (AAPPTec, 
Louisville, KY). Overnight coupling steps were performed manually in 8 ml fritted polysterene 
tubes. The protocols for the peptide general synthesis, cleavage, Cu catalyzed on bead click 
reaction, and HPLC protocols followed are described in chapter 2. The synthesis and 
characterization of the individual peptides follow:  
Target phospho-peptide:  
The 32mer target peptide sequence, amino acids 450-481 of Akt2, 
ITPPDRYDSLGLLELDQRTH-FPQF(pS)YSASIRE was synthesized on Rink Amide MBHA resin, 
using the Titan 357 peptide synthesizer. Fmoc-Ser(OPO3Bzl)-OH (AaPPTec) was used for the 
incorporation of phosphoserine in the peptide. Calculated mass: [M+H]+ 3832.  Observed mass: 
[M+H]+ 3831.97 
 
Figure 3.3: Sequence of the phospho peptide used as target epitope. 
The target phospho-peptide, amino acids 450-481 of Akt2, is phosphorylated at Ser474. The 
hydrophobic motif is highlighted in red. 
 
 
 
Synthesis of mono-L:  
Fmoc-NH-PEG2-OH was coupled using standard Fmoc protocol on Biotin Novatag resin. 
1.5 equivalents of D,L-Fmoc-azidolysine were coupled on the resin followed by acylation. On 
bead Cu catalyzed click reaction was carried out following described protocol using 2 equivalents 
of Fmoc-D-Pra-OtBuS2. After washes with a copper chelating solution, the peptide was acylated. 
The resultant molecule S1 was cleaved off the resin using TFA cleavage solution. The crude solid 
was used in further synthesis. The peptide wkvkl was made on Rink Amide MBHA resin 
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(Anaspec) following standard Fmoc SPPS synthesis protocol. 1.5 equivalents of S1 were then 
coupled to the peptide.  After TFA cleavage the mono-L was purified using a gradient of water 
and acetonitrile and 0.1% TFA on the RP-HPLC. Calculated mass:  1494.8.  Observed mass: 
1494.6  
Figure 3.4: Synthesis of the intermediate S1 for the bulk synthesis of the monoligand 
peptide mono-L. 
 
 
 
Figure 3.5: Structure of the monoligand peptide mono-L developed against the target 
peptide. 
S1 is coupled to peptide D-Pra-wkvkl to synthesize mono-L. 
 
 
  
 
92 
Synthesis of compound 4: 
  Fmoc-NH-PEG2-OH was coupled using standard Fmoc protocol on Biotin Novatag resin. 
1.5 equivalent of D,L-Fmoc-azidolysine was coupled on the resin followed by coupling of 1.5 
equivalent of compound 2. The resin was then subjected to on bead Cu catalyzed click reaction 
with Fmoc - D-Pra-OtBu.  The excess copper was removed by washing with the copper chelating 
solution. 5-Azido-pentanoic acid was then coupled. The resulting peptide S2 was TFA cleaved 
and lyophilized. The crude was used in further synthesis.  
The peptide wkvkl was made on Rink Amide MBHA resin (Anaspec) following standard 
Fmoc SPPS synthesis protocol. 1 equivalent of S2 was then coupled to the peptide. The peptide 
was cleaved off using TFA cleavage solution. 2 equivalents of zinc acetate was dissolved in 
methanol and added to 1 equivalent of crude peptide and stirred overnight at room temperature. 
The solvent was removed under reduced pressure and the solid, compound 4, was purified using a 
gradient of water and acetonitrile and 0.1% TFA on the RP-HPLC. Mass calculated: [M+Na] 
2291, [M+Na.TFA] 2404 Mass observed: [M+Na] 2289.98, [M+Na.TFA] 2403.95  
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Figure 3.6: Synthesis of the zinc chelator - monoligand complex compound 4 used in 
biligand screen of Akt2. 
 
 
 
Synthesis of bi-L:  
Fmoc-NH-PEG2-OH was coupled using standard Fmoc protocol on Biotin Novatag resin. 
1.5 equivalent of D,L-Fmoc-azidolysine was coupled on the resin followed by acylation of the 
amine terminal. On bead click reaction was carried out with 2 equivalents of Fmoc-D-Pra-OtBu. 
After washes with copper removing solution, 5-azido-pentanoic acid was coupled. After TFA 
cleavage the resultant molecule S3 (Figure 3.7) was lyophilized and the crude solid was used in 
further synthesis. The peptide wkvkl was made on Rink Amide MBHA resin (Anaspec) following 
standard Fmoc SPPS synthesis protocol. 1 equivalent of S3 was then coupled to the peptide on 
bead. Fmoc-D-Pra-OtBu was then clicked to the azido functionality on bead. After washes with 
the copper chelating solution, the peptide was further extended to hngyf on the N terminal using 
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standard Fmoc SPPS synthesis. After TFA cleavage the biligand was purified using a gradient of 
water and acetonitrile and 0.1% TFA on the RP-HPLC. Mass calculated: 2309.7 Mass observed: 
2309.4  
Figure 3.7: Synthesis of intermediate S3 for bulk synthesis of the biligand bi-L, biligand 
anchor anchor-3C and the triligand C– term–tri-L. 
S3 is used in the synthesis of the bi-L, Anchor-3C and C– term–tri-L. 
 
 
 
Figure 3.8: Structure of the biligand bi-L isolated in the screen against the target peptide. 
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Synthesis of Anchor-3C:  
The peptide NH2-wkvkk(Alloc) was made on Rink Amide MBHA resin following 
standard Fmoc SPPS synthesis protocol. 1 equivalent of S3 (Figure 3.7) was then coupled to the 
resin.  On bead click reaction was carried out overnight using 1.5 equivalents of  Fmoc-D-Pra-
OtBu. After washes with the copper chelating solution, the peptide was further extended to hngyf 
on the N terminal using standard Fmoc SPPS synthesis. Then it was acylated again. The alloc side 
chain of Fmoc-D-lysine(Alloc)-OH was deprotected using standard alloc deprotection 
techniqueS3. Then 4-pentynoic acid was coupled.  After TFA cleavage, Anchor-3C was purified 
using a gradient of water and acetonitrile and 0.1% TFA on the RP-HPLC. Mass calculated: 
2446.8  Mass observed: 2446.5 
Synthesis of Anchor-3N:   
Fmoc-NH-PEG2-OH was coupled using standard Fmoc protocol on Biotin Novatag resin. 
1.5 equivalent of D,L-Fmoc-azidolysine was coupled on the resin followed by acylation using 
acetic anhydride and 2,6-lutidine solution in DMF. On bead click reaction with Fmoc-D-Pra-
OtBu was carried out. After washes with copper chelating solution Fmoc-L-azidolysine was 
coupled. Following removal of the Fmoc protecting group, the amine terminal was acylated. After 
TFA cleavage the resultant molecule S4 (Figure 3.9) was lyophilized and the crude solid was 
used in further synthesis. The peptide wkvkl was made on Rink Amide MBHA resin. 1.5 
equivalents of S4 were then coupled to the peptide. On bead click reaction was carried out with 
two equivalents of Fmoc-D-Pra-OtBu. After washes with copper removing solution, the peptide  
was further extended to hngyf on the N terminal using standard Fmoc SPPS synthesis. Fmoc-L-
azidolysine was then coupled, followed by acylation of the amine terminal. After TFA cleavage 
Anchor-3N was purified using a gradient of water and acetonitrile and 0.1% TFA on the RP-
HPLC. Mass calculated: 2534.9 Mass observed: 2534.6 
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Figure 3.9: Synthesis of intermediate S4 for the bulk synthesis of the biligand anchor 
anchor-3N and the triligand N-term-tri-L. 
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Figure 3.10: Structure of biligand anchor peptides Anchor-3N and Anchor-3C. 
A. Anchor-3N is used to the Akt2 protein before screening against a alkyne containing OBOC 
library A. Anchor-3C is used to the Akt2 protein before screening against a alkyne containing 
OBOC library. 
 
 
 
Synthesis of N-term-tri-L:  
Side chain protected version of Ac-D-Pra-yyrfG-CONH2 was made on Amide Sieber 
resin. The protected peptide was cleaved off using 1% TFA in DCM and purified using a gradient 
of water and acetonitrile and 0.1% TFA on the RP-HPLC. Anchor-3N was made on resin as 
described and then acylated using standard acylation method. On bead click reaction was carried 
out for the bead bound Anchor-3N with 2 equivalents of side chain protected purified peptide Ac-
yyrfG-CONH2. The resin was washed with copper chelating solution. The peptide was cleaved 
off the resin with the TFA cleavage solution and purified using a gradient of water and 
acetonitrile and 0.1% TFA on the RP-HPLC. Mass calculated: 3417.9 Mass observed: 3417.5 
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Figure 3.11: Molecular structure of the triligand N-term-tri-L. 
 
 
 
 
 Synthesis of N-term-tri-dimer:  
Fmoc-NH-(PEG)2-OH was coupled using standard Fmoc protocol on Biotin Novatag 
resin. Fmoc-Dap (Fmoc)-OH was then coupled, providing two amine terminals for further amino 
acid couplings, which happened in parallel. Following the coupling of Fmoc-NH-(PEG)2-OH, 
wkvkl was synthesized on both of the amine termini. The intermediate compound S5 (Figure 
3.12) was then added to provide two azide click handles. After click reaction with Fmoc-D-Pra-
OtBu, the peptide was extended to hnGyf on the N terminal and then acylated.  On bead Cu 
catalyzed click reaction was carried out with the resin bound peptide and 2 equivalents of side 
chain protected HPLC purified Ac-D-Pra-yyrfG. After treatment with the Cu chelating solution, 
the peptide was dried, cleaved off resin with TFA cleavage solution and HPLC purified. Mass 
calculated: 7245.2 Mass observed: 7244.97  
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Figure 3.12: Synthesis of intermediate compound S5 for bulk synthesis of the triligand N-
term-tri-L-dimer. 
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Figure 3.13: Molecular structure of the triligand N-term-tri-dimer. 
 
 
 
Synthesis of D-Lys (pentyne) amide:  
Boc-D-Lys(Fmoc)-OH was coupled with rink amide resin. Then 4-pentynoic acid was 
coupled with it, after standard piperidine deprotection. The dried resin was cleaved with TFA 
cocktail and purified using a gradient of water and acetonitrile and 0.1% TFA on the prep-HPLC. 
Mass calculated: (M+H) 225 Mass observed: 226 
Synthesis of C-term-tri-L:  
Ac-L-Az4-hdggf (Az4 = azidolysine) was made on Rink Amide MBHA resin. On bead 
click reaction of the peptide on resin with D-Lys(pentyne) amide was carried out overnight at 
room temperature with 2 equivalents of D-Lys(pentyne) amide. The resin was washed with the 
copper chelating solution and further extended to wkvk on the N terminal using standard Fmoc 
SPPS synthesis. Then, 1.5 equivalent of S3 was coupled to the peptide. An on bead click reaction 
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was carried out with Fmoc-D-Pra -OtBu. After washes with copper chelating solution, the peptide 
was further extended to hngyf on the N terminal using standard Fmoc SPPS synthesis. The dried 
resin was cleaved with TFA cleavage solution and purified using a gradient of water and 
acetonitrile and 0.1% TFA on the RP-HPLC. Mass calculated: 3199.6 Mass observed: 3198.4. 
  
Figure 3.14: Molecular structure of the triligand C-term-tri-L. 
 
 
 
 
3.3 Results and discussion 
3.3.1 Synthesis of the dinuclear zinc chelator Zn2L-Az4-PEG2-Biotin and 
verification of its binding to phospho amino acids and phosphopeptide 
Dinuclear Zn(II)-dipyridylamine (DPA) complexes, due to their avidity for phosphate 
anions over other anions such as carbonate, sulphate, or chloride, have been used, for example, in 
the development of fluorescence-based sensors of kinase activity 21, for the detection of bacterial 
infection sites 22. In this work, the property of dinuclear Zn(II)DPA to selectively bind to the 
phosphate anion is combined with the technique of in situ protein catalyzed click chemistry to 
develop a new strategy of chemical epitope targeting. Ethyl 3,5-bis((bis(pyridin-2-
ylmethyl)amino)methyl)-4-hydroxybenzoate (compound 1,Figure 3.1) was synthesized by the 
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aromatic Mannich reaction of 2.5 equivalents of N,N –di(2-picolyl)amine and 3.75 equivalents of 
formaldehyde with ethyl 4-hydroxobenzoate under reflux conditions. Alkaline hydrolysis of the 
ester yielded 3,5-bis((bis(pyridin-2-ylmethyl)amino)methyl)-4-hydroxybenzoic acid (compound 
3, Figure 3.1), a heptadentate ligand. The carboxylic acid group on 2 is compatible with solid 
phase Fmoc based peptide synthesis. To add an azido tag and a biotin tag to 2, Fmoc -azidolysine 
was coupled using standard SPPS protocols to Biotin PEG Novatag resin, followed by the 
coupling of 3 to the resin. After cleaving the compound off the resin with trifluoroacetic acid and 
subsequent HPLC purification, a treatment in solution with Zinc acetate yielded the desired 
ligand Zn2L-Az4-PEG2-Biotin (Figure 3.1). The property of Zn2L-Az4-PEG2-Biotin to selectively 
bind to phospho-serine, phospho-tyrosine and a phospho-peptide (pSrc substrate) was 
demonstrated by incubating Zn2L-Az4-PEG2-Biotin with the respective amino acids or peptide in 
borate buffer, followed by Maldi TOF in a positive mode, that yielded the peaks for Zn2L-Az4-
PEG2-Biotin -pSer, Zn2L-Az4-PEG2-Biotin -pTyr and Zn2L-Az4-PEG2-Biotin -pSrc complexes23 
(Figure 3.2). 
 
3.3.2 Modification of peptide fragment of Akt2 
  For the development of an anchor ligand targeted against the Akt2 C-terminal phospho-
peptide, we reacted Zn2L-Az4-PEG2-Biotin with the phosphorylated, C-terminal Akt2 polypeptide 
(amino acids 450-481 with p-S474) to provide an initial (temporary) in situ click reaction site 
adjacent to the phosphorylated residue.  This complex is Complex-1 (Figure 3.15). 
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Figure 3.15: Complex-1 is formed by the reaction of dinuclear zinc complex with the 
phospho-peptide epitope. 
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3.3.3 Identification of a 1o ligand targeted against Akt2 C terminal fragment 
Complex-1 was incubated with an acetylene-containing one-bead-one-compound 
(OBOC) 6-mer peptide Library A (Figure 3.16), which consisted of all possible combinations of 
18 non-natural and artificial amino acids in 5 positions (Table 3.1). The OBOC library was 
probed with a monoclonal anti-biotin antibody conjugated with Alkaline Phosphatase (AP) 
enzyme (anti biotin mAb–AP).  The hit beads turn turquoise colored upon treatment with the 
chromogenic BCIP (5-Bromo-4-chloro-3-indolyl phosphate) substrate for AP1,2. These hit beads 
(around 5000) contain both the desired in situ click hits, as well as false positives that exhibit 
binding to the anti biotin mAb–AP.  The hit beads were stringently washed to remove all non-
covalently bound biological and chemical agents, then rescreened with Complex-1, then probed 
with biotin bound anti biotin mAb – AP .The true hit beads remain clear when treated with BCIP.  
Those true hits were sequenced by Edman degradation to identify candidate 1o ligands.   This 
dual screening strategy ensures that the beads identified as true hits have clicked product on-
bead3,4.  Remarkably, this strategy produced only true 2 hits (from a starting (oversampled) 
library size of 1.9 million sequences), which sequenced to yield the same peptide: D-Pra-wkvkl, 
which, when appended to azidolysine, (PEG)2 and biotin label, formed mono-L (Figure 3.5).  
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Figure 3.16: Screening strategy for developing a capture agent targeting the C terminal 
hydrophobic motif of the Akt2 protein. 
Zn2L-Az4-PEG2-Biotin is coupled with the Akt2 32-mer C-terminal fragment containing p-S474 
through the interaction to create Complex-1. Complex-1 is screened against Library A to yield 1o 
ligand candidates, from which a consensus 1o ligand (mono-L) is identified. In the next round of 
ligand development, compound 4 is coupled to the C-terminal fragment through the Zn chelator 
to create Complex-2. Complex-2 is screened against Library B to identify candidate 2o ligands, 
from which a consensus biligand (bi-L) is prepared.   
 
 
 
3.3.4 Identification of a biligand targeted against Akt2 C terminal fragment  
We used a similar strategy to identify candidate 2o ligands. The Zn chelator Zn2L-Az4-
PEG2-Biotin was modified with peptide wkvkl and an azide on the N terminal to form compound 
4, which was then reacted with the C-terminal 32-mer polypeptide fragment of Akt2 containing 
p-S474 to form Complex-2 (Figure 3.16).  Library B was screened against two concentrations of 
Complex-2.  To eliminate background binders to the detection antibody or to compound 4, pre-
screens were performed.  The pre-screening conditions replicated actual screen conditions, except 
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that compound 4 was used in place of Complex-2. In the prescreen, Library B, equilibrated in the 
binding buffer, was incubated with compound 4, and then probed with anti-biotin mAb–AP 
following the screening protocol. Colored beads were removed from the library, and the clear 
beads are subjected to a series of stringent washes and then screened against Complex-2. The hit 
beads from that screen were then treated with guanidium chloride and sequenced. The sequences 
exhibited a high homology, and are listed in Table 3.3 and Table 3.4. Based on the sequence 
homology, four peptides were chosen as potential 2o ligand candidates.  Simpler versions of the 
biligand candidates were made substituting a clicked triazole with histidine. These ligands were 
then compared in an immunoprecipitation assay for their ability to pulldown Akt2 from OVCAR3 
cell lysate. The best performing biligand was resynthesized in bulk, this time containing no 
substitutions, (bi-L) and further characterized. 
 
3.3.5 Development of Triligands against full length Akt2 protein  
The biligand was separately modified at both the N- and C-termini, with acetylene- and 
azide-containing amino acids, respectively, to form Anchor-3N and Anchor-3C (Figure 3.10) for 
in situ click triligand screens.  Both screens involved pre-clear steps similar to that described 
above.  The major difference was that these screens utilized the full length active Akt2 as the 
target/catalyst, and employed Libraries A and C respectively.  Several candidate 3o ligands were 
identified from these screens.  A subset was selected for scale-up and testing as candidate 
triligands (Table 3.6 and Table 3.7). The two triligands C-term-tri-L, N-term-tri-L (Figure 3.14, 
Figure 3.11) were synthesized. Since dimerizing of a peptide ligand may create a ligand with 
higher affinity to the protein, the ligand N-term-tri-L, having high affinity, was dimerized using a 
diaminopropionic acid and polyethylene glycol spacer. N-term-tri-L-dimer (Figure 3.13) were 
synthesized in bulk and characterized. 
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Figure 3.17: Scheme describing triligand screens using anchor-3N and anchor-3C. 
Anchor-3N and Anchor-3C are synthesized by modifying bi-L with an azide group at the N- 
terminal and an alkyne group at the C-terminal of the peptide, respectively. Anchor-3N and 
Anchor-3C are separately screened against Library A and Library C in the presence of full length 
Akt2 to identify candidate 3o ligands, from which the consensus triligands are identified.  The 
screens involve various other steps (not shown) that were designed to remove false positive hits.  
All hit beads are identified using alkaline-phosphatase (AP)-labeled anti-biotin antibody as a 
means of detecting the on-bead triazole linked product.   
 
 
 
3.4 Conclusion 
In this chapter I have described the development of the epitope targeting strategy. We 
modified the peptide fragment from C terminal of Akt2 to incorporate an azide handle. This 
modified complex acts as the scaffold and a reactant when exposed to a peptide library with a 
complementary alkyne handle. Two rounds of ligand development were done with the peptide 
fragment to develop a biligand. In this biligand stage we decided to eliminate the phosphate 
binding dinuclear zinc complex, as this type of molecule can react with several biological 
molecules. Then we applied the strategy of developing Iterative In situ Click capture agents by 
screening against the entire protein, to yield several triligands. In the next chapter we shall 
discuss the characteristics of the developed ligands. It is to be noted that although the peptide 
modification was done using a dinuclear zinc chelator, there can be several other ways of 
achieving this goal, the simplest of which is direct amino acid substitution in the target peptide to 
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insert a click handle. In fact, our preliminary data with that method yielded sequences similar to 
the followed method. The epitope targeting strategy is a particularly valuable strategy when the 
target protein has posttranslational modifications like glycosylation or phosphorylation, which are 
difficult to express or purify. 
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Chapter  4: Characterization of protein capture agents developed 
against Akt2 
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4.1 Introduction 
In chapter 3, we discussed the chemical epitope targeting strategy and the development of 
multivalent ligands against the Akt2 protein through consecutive in situ target catalyzed click 
reaction. During the development of the various peptide arms from the 1° ligand to the 3° ligand, the 
resulting ligand is validated in at least one assay and the peptide arm showing the best affinity and 
specificity is further used in the next step of multivalent ligand development.   In this chapter we 
describe the assays used to choose the peptide arms, and characterize the final developed ligands in 
additional assays. We also explore the effect of the ligands on the kinase activity of the protein. The 
relative binding affinities of the ligands for Akt2 were determined through ELISA assays. The 
triligand candidates had low nanomolar binding affinities. The values are in agreement with the 
absolute values obtained through SPR experiments. Selectivity or specificity of each ligand were 
determined against the epitope and against the full protein. We demonstrate that the ligands bind 
selectively to the target C-terminal 32-mer polypeptide fragment of Akt2. Finally, we explored if 
the developed ligands have any effects on the kinase activity of the Akt2 protein. Remarkably, the 
two triligands, sharing the same biligand fragment, were found to have opposite effects on the 
kinase activity of the Akt2 protein. While one of the ligands enhances the kinase activity of the 
protein, the other ligand inhibits the kinase activity. 
 
4.2 Materials and Methods 
4.2.1 Materials 
Mouse anti biotin monoclonal antibody- Horse Radish Peroxide conjugate was purchased 
from Cell Signaling Technology. Anti His6 mouse monoclonal antibody, Akt2 phospho S474 
antibody and goat anti mouse IgG-Horse Radish Peroxide conjugate were bought from Abcam. 
Anti Akt (pan) rabbit antibody (11E7) and anti rabbit antibody- Horse Radish Peroxide conjugate, 
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used in Western blot and dot blot experiments, were purchased from Cell Signalling Technology. 
Biacore chip, reagents and buffers used in the SPR experiment were bought from GE Healthcare. 
High capacity Strepatvidin coated 96 well plates were obtained from Thermo Scientific. 96 well 
plates were bought from Nunc. TMB substrate for HRP, used in ELISA assays, was bought from 
KPL.  
4.2.2 Methods  
4.2.2.1 Peptide synthesis 
Synthesis of His6 tagged target phosphopeptide and off target peptide sequence: 
 The phosphorylated version of the target sequence, amino acids 450-481 of Akt2, with 
pS474, and the 33mer off target peptide (Akt2 amino acids 346-378) were synthesized on Rink 
Amide MBHA resin, using standard Fmoc based SPPS protocols. Fmoc-NH-(PEG)2-OH was 
then coupled with each peptide. Then six successive couplings were done with Fmoc-L-His(Trt)-
OH. The peptides were cleaved by TFA/TES/ddH2O, precipitated in cold ether and purified using 
a gradient of water and acetonitrile and 0.1% TFA on the RP-HPLC. Target phospho-peptide: 
Calculated mass: 4858.2 Observed mass: 4858.1 Scrambled phospho-peptide: Calculated mass: 
5071.5 Observed mass: 5071.5  
4.2.2.2 ELISA for mono-L and bi-L  
On a nunc 96 well Immunosorp plate, 1 µg of active Akt2 per well was immobilized for an 
hour in carbonate buffer (pH 9.6). The wells were blocked with ethalonoamine for two hours and 
then with SuperBlock blocking buffer in PBS (Thermo Scientific) overnight at 4°C. The wells 
were washed with PBST. A half dilution series of the ligand (concentrations from 50 nM to 10 
µM) were made in the buffer (1% Superblock/ 0.05% Tween 20/PBS). The immobilized protein 
was shaken with the ligand solution series for 6 hours at 4°C, then washed five times with 
binding buffer. The wells were treated with Antibiotin-HRP antibody (1:10,000 dilution of 1 
mg/ml stock) in binding buffer for an hour at 4°C. After four washes with PBS and one wash with 
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PBST (0.05% Tween-20/PBS), the wells were treated with TMB substrate. The reaction was 
quenched with 0.5 M H2SO4. Absorbance was measured at λ = 450 on a 96-well plate reader. 
The Net A450 was obtained by subtracting the respective absorbance values for no immobilized 
protein from the values obtained for the ligand protein interaction. These values were normalized 
and the data fitted by non-linear regression in GraphPad Prism software. 
4.2.2.3 ELISA for N-term-tri-L and C-term-tri-L 
200 nM solutions of the biotinylated triligand in binding buffer (1% Superblock, 0.05% 
Tween 20/ TBS pH 7.5) were added to the wells of a High Capacity Streptavidin 96 well plate 
(Thermo Scientific) and shaken for two hours at room temperature.  The plate was blocked with 
1% BSA/ 0.05% Tween 20/ TBS pH 7.5. The wells were washed with binding buffer five times. 
Active His6 tagged Akt2, from 1.15 nM to 450 nM concentrations, was added and the plate 
shaken overnight at 4°C. The wells were washed three times with the binding buffer, then treated 
for an hour with a 1:1000 dilution of anti His6 mouse monoclonal antibody.   A 1:10,000 dilution 
of goat anti mouse antibody-Horse Radish Peroxide conjugate (Abcam) in binding buffer was 
added to the wells for an hour. The plate was washed, treated with TMB and quenched with 
H2SO4, and the absorbance measured as described in the previous paragraph. The Net A450 
(subtracting the absorbance value for no immobilized ligand) was fitted by non-linear regression 
in GraphPad Prism software. 
4.2.2.4 OVCAR3 lysate pulldown assay  
OVCAR3 cells were grown in RPMI-1640 media containing 10% fetal bovine serum 
and 0.01 mg/ml bovine insulin.  Passage five cells were grown to ~ 80% confluence. Cells were 
lysed with lysis buffer (10 mM Tris-Cl (pH = 7.5), 100 mM NaCl, 1% (v/v) Triton X-100, 0.1% 
SDS (w/v), 0.5% deoxycholate, 1 mM DTT, 1 mM EDTA, 1X PhosStop phosphatase inhibitors 
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(Roche), 1X Complete protease inhibitors (Roche)) and the amount of protein measured using 
BCA Protein Assay Kit (Pierce Biotechnologies, Inc). 
Streptavidin-agarose resin solution (EMD) was swelled in TBST (25 mM tris 
chloride, pH= 7.5, 150 mM NaCl, 0.05% Tween-20). Each of the biotinylated ligands was 
immobilized on the Streptavidin-agarose resin by adding 7.2 µL of 1 mM ligand stock (DMSO) 
to 10 µL of the swelled Streptavidin-agarose resin. After shaking overnight at 4°C, 50 µM D-
biotin was added to the resin to block any remaining sites. The resin was washed with TBST five 
times, for fifteen minutes each. The resin was then swelled in binding buffer for two hours. To 
each of the immobilized ligands 150 µL OVCAR3 cell lysate (0.8 mg/ml) and binding buffer was 
added to a final volume of 250 µL. The tubes were shaken at 4°C for 18 hours.  The beads were 
then were extensively washed, three times for fifteen minutes in binding buffer, three times 
(fifteen minutes) in TBST, and three times (fifteen minutes) in TBS to remove unbound proteins. 
The resin bound proteins were eluted by adding 40µL of 2X SDS-PAGE sample loading buffer 
(BioRad) and heating at 95°C for 10 minutes. 10 µL of each sample was loaded on a 12% SDS-
PAGE gels (BioRad) and run for 50 minutes at 120 volts. The gel was transferred to a 
nitrocellulose membrane, blocked for 2 hours at 4°C with 5% non-fat milk, and treated overnight 
at 4°C with a 1:1000 dilution of pan-Akt rabbit monoclonal antibody (11E7, Cell Signaling 
Technology) in 0.5% non-fat milk. The membrane was washed and treated for an hour with a 
1:10,000 dilution of monoclonal mouse anti-rabbit- HRP secondary antibody (Cell Signaling) in 
0.5% milk. After five washes of five minutes each with TBST and one wash of five minutes with 
TBS, the blot was developed with West Dura ECL substrate (Thermo Scientific) and imaged on 
film. 
4.2.2.5 Non-radioactive kinase assay to evaluate effect of ligands on Akt2 kinase activity 
The non-radioactive kinase assay kit for Akt2 was purchased from Cell Signalling. Serial 
dilutions of 2 mM ligand solution were made in filtered DMSO. Kinase reactions were set up in 
  
 
116 
1X kinase buffer (25 mM trisHCl (pH 7.5), 10 mM MgCl2, 0.01% Triton-X, 1X Complete 
protease inhibitor (Roche), 1X Phosstop phosphatase inhibitor (Roche)), each 25 µL reaction 
mixture containing 400 ng Akt2, 400 ng GST-GSK-3α/β fusion protein, 500 mM ATP and 0.5 µL 
of peptide solutions in DMSO or DMSO only. Reactions were allowed to proceed for 30 minutes 
at 30°C. The reactions were quenched by addition of 2.5 µL of a 500 mM DTT/ 20% SDS 
solution.  
For dot blot, 2 µL of each of the reaction mixtures were spotted in triplicate on a 
nitrocellulose membrane. The membrane was blocked in 5% nonfat milk/TBST for an hour at 
4°C, and treated overnight at 4°C with a 1:200 dilution of Phospho GSK-3α/β Ser (21/9) rabbit 
antibody (Cell Signaling) in 0.5% milk/TBST. Following washes, the membrane was treated with 
a 1:2000 dilution of mouse anti-rabbit –HRP antibody for an hour at 4°C. After four five minute 
washes with TBST, and one five minute wash with TBS, the membrane was treated with West 
Dura ECL substrate (Thermo Scientific) and imaged on film. 
For the Western blot, an additional reaction mixture was also prepared using a 1:2.5 
dilution of anti pS473 antibody (Cell Signaling) in the kinase buffer instead of the peptide ligand 
or DMSO. This reaction mixture was treated similar to the other kinase reaction mixtures. After 
30 minutes the reactions were quenched with addition of 3X SDS sample buffer. The solution 
was heated at 95°C for five minutes. 10 µL from each sample was loaded on a any KD SDS gel 
(Biorad) and run for an hour at 110 volts. Following semidry transfer of the gel to a nitrocellulose 
membrane, the membrane was blocked, treated with Phospho GSK-3α/β Ser (21/9) rabbit 
antibody and anti-rabbit –HRP antibody as described in the previous paragraph. After four five 
minute washes with TBST, and one five minute wash with TBS, the membrane was treated with 
West Dura ECL substrate (Thermo Scientific) and imaged on film. 
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4.2.2.6 Epitope Targeting Selectivity Assay 
  1.25 µM biotinylated ligand was prepared by diluting the 1 mM stock in binding buffer 
(25 mM tris chloride, pH= 7.4, 150 mM NaCl, 0.1% BSA, 0.05% Tween 20).  The prepared 
ligand solution or 0.125 % DMSO in buffer (buffer control) was immobilized on a High Capacity 
Streptavidin 96 well plate (Thermo Scientific). After washing away the excess ligand, the plate 
was blocked overnight with 1% BSA /25 mM tris chloride, pH= 7.4/ 150 mM NaCl, 0.05% 
Tween 20. 2.5 µM solutions of the His6 tagged target phosphopeptide epitope Akt2 amino acids 
450 – 481 or the His6 tagged off target peptide Akt2 amino acids 346-378 (His6 – PEG – off-
target) were added to each of the wells.  Following three washes with the binding buffer, the plate 
was treated for an hour with a 1:1000 dilution of anti His6 mouse monoclonal antibody. A 
1:10,000 dilution of goat anti mouse antibody-Horse Radish Peroxide conjugate in binding buffer 
was added to the wells. The plates were washed four times, five minutes each, with 0.05% Tween 
20/ TBS (25 mM tris chloride, pH= 7.5, 150 mM NaCl) and once with TBS (25 mM tris chloride, 
pH= 7.5, 150 mM NaCl). Color was developed by adding TMB substrate (KPL) to each well. The 
reaction was quenched with 0.5 M H2SO4. The A450 measured on a 96-well plate reader. The 
Net A450 was obtained by subtracting the absorbance value for the blank control (no 
immobilized ligand) from each of the triplicate values obtained for the ligand-epitope interaction. 
4.2.2.7 Protein Isoform Selectivity Assay 
The selectivity assay with full length Akt1, Akt2 and Akt3 is performed following the 
protocol in section 4.2.2.6, using 25 nM protein instead of 2.5 µM His6 tagged peptide epitope.  
4.2.2.8 Measurement of binding affinity of N-term-tri-L and N-term-tri-L-dimer by 
Surface Plasmon Resonance  
  A Biacore T100 machine was used for SPR experiments. A Streptavidin Chip  (Series S,  
G.E. Healthcare) was conditioned as per manufacturer’s recommendation.  A stock of 1 mM 
biotinylated ligand was diluted into HBSP+ Buffer (G.E. Healthcare) to a final concentration of 
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100 nM and ~150 RU was immobilized on the chip. Serial dilutions (450 nM to 1 nM) of the 
Akt2 protein were made in HBSP+ buffer for the experiment with the immobilized N-term-tri-L. 
For the N-term-tri-L-dimer, serial dilutions of Akt2 from 45 nM to 0.0086 nM were made. The 
solution was flowed over the chip at 50 µL/min. Binding and dissociation were carried out at 
10°C with a contact time of 350 sec, a dissociation time of 390 sec, and a stabilization time of 
200 sec, with buffer blanks between each concentration.  The response was corrected using an 
unmodified reference flow cell. Biacore Evaluation software was used to calculate the 
dissociation constants.  
4.3 Results and discussion 
4.3.1 Characterics of PCC ligands developed against Akt2  
Biligand candidates were prepared from the 1o ligand and each of the 2o ligands using the 
Cu(I)-catalyzed click reaction,28,29 and the biligands were then compared in an 
immunoprecipitation assay for their ability to pulldown Akt2 from OVCAR3 cell lysate. The 
highest performing peptide biligand (bi-L) exhibited superior performance to mono-L (Figure 
4.2), and was selected for further characterization. The affinity of bi-L was estimated, from a 
direct ELISA involving the full Akt2 protein, to be 1.3 µM. The N-term-tri-L exhibited the best 
performance in the selectivity immunoprecipitation assays from OVCAR3 cell lysate (Figure 
4.1). The affinity of the N-term-tri-L and C-term-tri-L were estimated from single component 
ELISA assays to be 19 nM and 124 nM, respectively (Figure 4.2).  We note that the 3o ligand on 
the C-term-tri-L is remarkably similar in sequence to the 2o ligand arm, indicating that both arms 
may be competing for the same spot on the protein for this triligand.  
We carried out selectivity assays on bi-L and both triligands to determine the level of 
epitope selectivity. To this end, we performed an ELISA assay, comparing the binding of the 
ligands to either the C-terminal 32-mer polypeptide fragment of Akt2, or an off target 32-mer 
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polypeptide Akt2 fragment (corresponding to residues 346 through 378) that is similarly surface 
exposed and unstructured in the full length protein. All the three capture agents exhibited a high 
selectivity for the C-terminal 32-mer relative to the other polypeptide fragment (Figure 4.3)  
The selectivity of the N-term-tri-L and C-term-tri-L for Akt2 over its isoform Akt1 and 
Akt3 was determined at the epitope level and against the full-length protein (Figure 4.4). One of 
the triligands, C-term-tri-L is highly selective for the peptide epitope of Akt2, and bind 
significantly less to the highly homologous C terminal epitopes of isomeric proteins Akt1 and 
Akt3. The same trend is observed in the binding of the ligands to the full-length Akt isoform 
proteins. 
The absolute affinities of the high affinity ligands, N-term-tri-L and N-term-tri-L-dimer 
were measured by Surface Plasmon Resonance (SPR), by immobilizing the biotinylated ligand on 
the SPR chip and measuring the responses for various concentrations of the analyte, the full 
length active Akt2 protein. The absolute affinity of N-term-tri-L was obtained as 10 nM from 
steady state fit on Biacore T100 evaluation software, which is very close to the affinity measured 
in the ELISA (19 nM).  The N-term-tri-L-dimer for Akt2, having two binding sites on the ligand, 
could not be fitted to the simplest 1:1 Langmuir binding model. The sensograms, when fit to the 
more appropriate model of 1:1 binding with mass transfer1, yielded a KD of 6.25 nM (Figure 4.5).  
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Figure 4.1: Immunoprecipitation and Western Blot assays showing the performance of the 
various PCC Agents.  
Akt2 is pulled down from the lysate of an ovarian cancer cell line Acetyl-glycine-biotin is used as 
the control.  
 
 
Figure 4.2: ELISA assays demonstrating use of PCC Agents. 
 PCC agents used as surface-localized capture agents (for N-term-tri-L, C-term-tri-L) or as 
detection agents (for mono-L, bi-L). This type of assays provides relative affinity measurements, 
which are given as EC50 values in the key. 
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Figure 4.3: Epitope specificity assay.  
The various triligand PCC agents are used as capture agents for the peptide epitope. The 
biotinylated capture agents are immobilized on a Streptavidin plate, and then probed with the His6 
tagged target or control peptides. The target peptide (Akt2 450-481) with pS474 shows a distinct 
binding affinity for the capture agents compared to the control peptide (Akt2 346-378). The C-
term-tri-L also significant selectivity for the Akt2 epitope compared to the corresponding regions 
in Akt1 (449-480) and Akt3 (448-479). 
 
 
 
Figure 4.4: Selectivity of triligands for the full length Akt isoform proteins. 
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Figure 4.5: SPR measurements of triligands. 
A. Sensograms from Surface Plasmon Resonance (SPR) experiment, immobilizing N–term-tri-L 
on SA chip and using Akt2 protein as the analyte. B. Steady state dissociation constant is 
measured by taking an average of the RUs in steady state over 3 time points, 150s, 200s and 250s, 
for each concentration of the protein. C. Sensograms from Surface Plasmon Resonance (SPR) 
experiment, immobilizing N –term-tri-L-dimer on SA chip and using Akt2 protein as the analyte. 
Because of the dimeric nature of the ligand, the sensograms fit best with the heterogenous ligand 
parallel model.  
 A. 
 
   
 
 
 
 
 
B.  
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C. 
 
 
 
 
 
 
 
 
 
4.3.2 Inhibitory Characteristics of the Akt2 Capture Agents  
Phosphorylation of Akt2 at Thr309 activates Akt2, but further phosphorylation at Ser474 
increases its enzymatic activity four to ten fold 2,3. In cancer cell lines4,5 and tissue samples6 the 
constitutively active PKB is phosphorylated at S473.  Overexpression and/or activation of Akt 
have been found to increase resistance of tumors to chemo7 or radio4 therapies. The importance of 
Akt as a therapeutic target has prompted several approaches towards selective Akt inhibition8.  
Akt small molecule kinase inhibitors are classified into two general classes:  type I ATP 
competitive inhibitors, and type II allosteric inhibitors that bind to the interface between the 
membrane docking pleckstrin homology domain (PHD) and the kinase domain9. These allosteric 
inhibitors exhibit no influence on the enzymatic activity of Akt when the PHD is removed8.  We 
recently reported on an peptide based allosteric inhibitor (Kinhibition ~3 µM) of the kinase domain 
of Akt 10that did not compete with either the ATP or peptide substrate binding sites, but appeared 
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to overlap at least partially with a commercial mAb that was directed at the C-terminus of the 
protein. As the phosphorylated hydrophobic motif around S474 (near the C-terminus) of Akt2 has 
been identified to act as an allosteric activator, we hypothesized that a ligand that was targeted 
near S474 would influence the enzymatic activity of Akt2. In this section, we explore the 
inhibitory characteristics of the various ligands developed here.   
The Akt kinase in vitro non-radioactive assay kit (Cell Signaling Technology) was used 
to estimate the influence of the ligands on the kinase activity of Akt2. In this assay, the active 
Akt2 is combined with its downstream effector GSK-3α/β substrate (GST-GSK3α/β fusion 
peptide substrate), ATP, and one of the peptide ligands (or dimethylsulfoxide (DMSO) for a 
control). The level of phosphorylation of GSK-3α/β, as measured by spotting the reaction 
mixture on a nitrocellulose membrane or by Western Blot, provides a readout for the Akt2 kinase 
activity (Figure 4.6). The bi-L and N-term-tri-L capture agents were found to activate Akt2, as did 
the commercial anti-p-Ser473 mAb (Figure 4.6).  However, the C-term-tri-L inhibits Akt2, with 
an IC50 (~500 nM) (Figure 4.6). Thus, the enzymatic activity of Akt2 is clearly hypersensitive to 
perturbations near the C-terminus, whether it is phosphorylation of S474, or structural 
perturbation of that (phosphorylated) terminus via ligand binding.  This hypersensitivity 
apparently works in both directions; perturbations of the ATP binding site can influence 
phosphorylation at the C-terminus.  Mechanistic studies of traditional ATP-competitive small 
molecule Akt inhibitors have highlighted this intricate structure/activity balance; ATP-
competitive inhibitors like A-443654 cause paradoxical hyperphosphorylation of Akt at both 
Thr308 and Ser473, and thus lead to reactivation of the protein after inhibitor dissociation11. 
  
  
 
125 
Figure 4.6: Influence of the PCC Agents on the enzymatic activity of the Akt2  kinase.   
A. The activity of Akt2 directly influences the phosphorylation state of GSK-3a/b, and detecting 
p-GSK-3a/b provides an assay readout, as a function of varying the nature or the concentration of 
a potential p-Akt2 inhibitor. B. Western blot analysis of p-GSK-3α/β levels as the various PCC 
Agents are added to influence the activity of p-Akt2.  DMSO is used as the control.  The p-GSK-
3α/β  levels for the N-term-tri-L, the bi-L, the N-term-tri-L-dimer, and the commercial p-S473 
mAb all imply that these agents activate p-Akt above baseline, with the N-term-tri-L-dimer and 
the mAb being the strongest activators.  The C-term-tri-L, however, serves as an inhibitor.  C.  
Quantitation of the inhibitory characteristics of the C-term-tri-L PCC Agent on p-Akt2.  Red 
points with error bars are from a dot blot analysis of p- GSK-3α/β, while the blue points are from 
a Western Blotting analysis (which only yielded a limited dynamic range in terms of % inhibition 
detectable).  The red line is a fit is to the dot-blot data points.  The assays yield similar IC50 values 
of 500 nM (dot blot) and 2 µM (Western). 
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4.4 Conclusions  
We report here on an epitope targeting strategy that, when combined with sequential in 
situ click chemistry, permitted the development of a series of peptide multi-ligands (called PCC 
Agents) that are targeted near the key activating phosphorylation site of Akt2.  The strategy relies 
on the use of dinuclear Zn(II)-dipyridylamine complex that binds to the phosphorylated residue12 
of interest,  and presents both a biotin label and an azide functionality near that site.  An 
advantage of the strategy is that it can be initiated using only a polypeptide fragment that 
represents the phosphorylated epitope of the target.  This permits stringent chemical 
characterization of all of the relevant chemical species used in the process.   
The strategy is utilized to identify an initial PCC Agent monoligand, a PCC Agent 
biligand and two PCC Agent triligands.  One of those triligands is further expanded into a dimer 
structure.   All of affinity agents are effective at detecting total Akt from ovarian cancer cell 
lysate, with improved performance being increasingly observed through the biligand and triligand 
stages.  The best triligand (and triligand dimer) exhibits an affinity in the 10 nM range, and 
epitope specificity is shown for the biligand and triligand PCC Agents.  
The p-Ser474 region near the C-terminus of Akt2 was explored here because 
phosphorylation of this hydrophobic motif leads to allosteric activation of Akt2, and so provides 
an interesting therapeutic epitope on the protein.  However, the epitope itself is not obviously 
amenable towards the development of traditional small molecule inhibitors.  Indeed, we find that 
PCC Agents developed against this epitope exhibit both inhibitory and activating characteristics, 
depending upon the detailed structure of the PCC Agent.  An obvious next step is to develop 
approaches for delivering these PCC Agents into live cells, and to further explore their potential 
as therapeutic inhibitors of Akt2.  Such studies are currently underway.   
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Chapter  5: Development of CuAAC cyclized one bead one compound 
peptide libraries and their application in the epitope targeting strategy 
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5.1 Introduction 
Cyclic peptides have been frequently used for drug discovery1,2, as molecular probes3, 
and as a protein detection agent. Whereas small molecules bind to proteins that have well 
developed hydrophobic pockets, a significant amount of protein interaction surfaces are relatively 
flat and distributed over a large contact surface area. So for surface binding, peptides perform 
better than small molecules. However, for peptide protein interactions to be high affinity, it is 
essential to have structural constraints in the peptide4. Cyclizing a peptide provides this 
constraint, at the same time increasing the protease resistance of the peptide5. 
For cyclic ligand development against proteins, phage display libraries have been 
frequently used. But a limitation of the phage display method is in incorporating unnatural amino 
acids such as D amino acids in the library. While innovative approaches, such as mirror image 
phage display 6, have been explored to overcome this disadvantage, it is by no means a trivial to 
introduce unnatural amino acids into phage display libraries. One Bead One Compound (OBOC) 
peptide libraries7,8 overcome this disadvantage, allowing easy incorporation of unnatural amino 
acids and other chemical modifications. However on bead screening and sequencing processes 
are not compatible with several categories of cyclization processes9-11. 
Here we describe the development of CuAAC cyclized peptide libraries that are 
compatible with OBOC screening. The developed cyclic library is used in epitope targeting 
strategy. In the epitope targeting strategy, we are trying to detect peptide-peptide interaction, 
which is typically weaker and tougher to detect than peptide-protein interaction. The property of 
cyclic peptide to have higher affinity than its linear one is particularly attractive for optimizing of 
the epitope targeted PCC agent development process.  To demonstrate of this process cyclic 
ligands were developed against a peptide epitope that has already been demonstrated to be good 
for developing peptide based ligands. This epitope is the C terminal fragment from the protein 
Akt2, amino acids 450-481, that contains pSer474.  
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Another motivation of this study is to study the cell penetrating properties of the isolated 
cyclic peptide inhibitor. Along with the robustness and compatibility of the cyclization 
procedures with on bead peptide chemistry, an important characteristic of the developed cyclic 
libraries is the nature of the cyclization linker. It has been found that an all hydrocarbon cross-
linker stabilizes the peptide and increases the cell penetrating property of the peptide12,13. For the 
triazole cyclized library, the hydrocarbon part, like the stapled peptide, should have a positive 
effect on the intracellular uptake of the cyclized peptide. The triazole unit acts as an amide 
bond14, and may or may not hinder the uptake of the cyclic peptide. The triazole, is, moreover, 
not susceptible to protease cleavage as amide bonds are. We have preliminary data that suggest 
the branched multiligand developed against Akt, as described in chapter 3 and 4, can be effective 
inside cells when tagged with the HIV derived TAT peptide sequence.  However the ideal 
situation would be to have a peptide based drug that has significant cell permeating property by 
itself. CuAAC cyclized peptides are promising in this respect. Among the four cyclic ligands 
isolated, one peptide Cy(yytytTz4) exhibits selective binding to both the peptide epitope and the 
Akt2 protein. We have preliminary data that the ligand acts as an inhibitor of kinase activity. 
 
5.2 Materials and Methods 
5.2.1 Materials 
Materials as described in sections 3.2.1 and 4.2.1 are used.  
5.2.2 Methods 
5.2.2.1 Synthesis of randomized peptide library and on bead cyclization  
Three comprehensive linear peptide libraries A, B and C were synthesized on Tentagel-S-
NH2 resin using standard SPPS library synthesis method. Each library was synthesized at a 10-
fold excess to ensure adequate representation of each library element. After the synthesis of each 
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library, all the beads in the linear library were subjected to an on bead CuAAC reaction, for 6 
hours at room temperature with 1.5 equivalents of CuI, 2.5 equivalents of ascorbic acid in 20% 
piperidine in DMF (Figure 5.1). After washes to remove the adsorbed Cu, the library was washed 
with DMF, methanol and DCM and dried. Random beads were picked from the library to be 
sequenced. The rest of the library was stored in NMP. The structure and details of the three 
libraries are shown in Table 5.1. 
 
Figure 5.1: Peptide cyclization on bead by the Cu catalyzed Azide Alkyne Cycloaddition 
(CuAAC) reaction. 
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Table 5.1: One Bead One Compound (OBOC) cyclic peptide libraries used in screens 
 
 
The linker containing the amino acid azidolysine clicked to L-Pra in a 1,4 disubstituted 
orientation is referred to as Tz4.  
Library 
(notation) 
Sequence Amino acids used 
Number of 
unique 
sequences 
A 
Cy(Pro-X1X2X3X4 
X5X6X7–Tz4) 
 
Xi =D-Ala, Gly, D-
Leu, D-Ile, D-Val, D-
Phe, D-Trp, D-Arg, 
D-His, D-Lys, D-Asp, 
D-Glu, D-Asn, D-
Gln, D-Ser, D-Thr, D-
Tyr, D-Pro. 
 
612,220,03
2 
B 
Cy(X1X2X3X4 
X5–Tz4) 
 
Xi =D-Ala, Gly, D-
Leu, D-Ile, D-Val, D-
Phe, D-Trp, D-Arg, 
D-His, D-Lys, D-Asp, 
D-Glu, D-Asn, D-
Gln, D-Ser, D-Thr, D-
Tyr, D-Pro. 
 
1889568 
C 
Cy(X1X2X3X4 
X5–Tz4) 
 
Xi =L-Ala, Gly, L-
Leu, L-Ile, L-Val, L-
Phe, L-Trp, L-Arg, L-
His, L-Lys, L-Asp, L-
Glu, L-Asn, L-Gln, L-
Ser, L-Thr, L-Tyr, L-
Pro. 
1889568 
X5
X6
X7
NH
HC
CH2
CH2
X4
X3
X2
X1
Pro
HN
CH
H2C
H2
C
H2
C
N
N
NH2N
O
O
HN
X4
X5
NH
HC
CH2
CH2
H2
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H2
C
H2C
CH
HN
X1 X2 X3
O
H2N
N N
N
HN
O
X4
X5
NH
HC
CH2
CH2
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C
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HN
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N
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O
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5.2.2.2 Synthesis of scrambled phospho-epitope and target phospho-epitope 
Akt2 450-481 (ITPPDRYDSLGLLELDQRTHFPQF(pS)YSASIRE) is used as the target 
phospho-epitope. The scrambled non-phosphorylated epitope has sequence 
ITPPDRYDSLGLLEL-QRTHYFFASQPSSIRE. For screening both peptides are synthesized on 
Rink Amide MBHA resin with a polyethylene glycol spacer (PEG2) and biotin on the N terminal.  
5.2.2.3 IR spectra  
HPLC purified lyophilized peptides were ground with KBr powder to make pellets. 
Measurements were made on a Vertex 70 FT-IR spectrometer (Bruker Optics). Scans of air were 
served as the background and were subtracted from the spectra. 
5.2.2.4 Screening cyclic OBOC library with peptide epitope 
 For isolating cyclic ligands against the peptide epitope, three consecutive libraries A, B 
and C were screened against the phospho-peptide. Each of the screens followed the following 
protocol: 500 mg of library resin were dried with DCM and afterwards, swelled and shaken 
overnight in binding buffer (25 mM trisCl, pH = 7.5, 150 mM NaCl, 0.1% BSA, 0.05% 
Tween20) at room temperature. Beads were incubated overnight with a solution of 500 nM of the 
scrambled phosphopeptide in binding buffer.  The beads were washed three times, for fifteen 
minutes each, with the binding buffer.  They were then treated for 1 hour at room temperature 
with a 1:1000 dilution of mouse monoclonal Anti-biotin antibody conjugated with Alkaline 
Phosphatase (mAb-AP) in screening buffer.  Following the screen, the beads were successively 
washed three times with each of the following buffers: 25 mM trisCl, pH = 7.5, 150 mM NaCl, 
0.1% BSA, 0.05% Tween20; 25 mM trisCl, pH = 7.5, 150 mM NaCl, 0.05% Tween20; 25 mM 
trisCl, pH = 7.5, 150 mM NaCl; 100 mM Tris-HCl, pH 9.0, 150 mM NaCl, 1 mM MgCl2) (AP 
buffer).  The library was treated with a 5-bromo-4-chloro-3-indolyl phosphate (BCIP) solution 
(33 uL BCIP in 10 mL AP buffer) for fifteen minutes.  The AP reaction was stopped using 0.1 M 
HCl, which denatures AP protein. Blue background hits were removed from clear ones using a 
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pipette. Clear beads were combined and transferred to a peptide synthesis vessel.  The beads were 
shaken in 7.5 M of guanidine-HCl pH = 2, which serves as a common protein denaturant, for 2 
hours at room temperature.  Afterwards, the library was washed with deionized water and treated 
with NMP to decolorize the blue beads. Following a wash with DCM, the clear beads were dried, 
then shaken overnight in binding buffer. 
The beads were screened overnight with a solution of 500 nM of the target phospho-
peptide in binding buffer. Following washes with the binding buffer, the beads were treated with 
a solution of mAb-AP. The same procedure as in the prescreening was conducted to obtain blue 
click hits. The beads were manually picked, washed with 7.5 M guanidium hydrochloride (pH 2) 
and water, and sequenced using the Edman Sequencer. 
 
Table 5.2: List of sequences obtained from screen against target epitope using cyclic library 
C. 
 
X1 X2 X3 X4 X5 X6 X7 
- Y V Y K S Tz4 
− V F A K V Tz4 
− I R Y Y S Tz4 
− Y Y T Y T Tz4 
 
5.2.2.5 ELISA for cyclic peptide Cy(yytytTz4) against full length Akt2 protein 
2 µM solution of the biotinylated cyclic peptide was prepared in binding buffer (TBS pH 
7.5, 0.05% Tween 20/0.1% BSA. 100 µL of the solution was added to each well of a High 
Capacity Streptavidin 96 well plate (Thermo Scientific) and the plate shaken for two hours at 
room temperature.  The wells were blocked with 1% BSA / TBS pH 7.5 / 0.05% Tween 20. The 
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wells were washed with binding buffer five times. Serial dilutions, from 1.15 nM to 450 nM, of 
active His6 tagged Akt2 (Abcam) were made in the binding buffer. 100 µl of each solution was 
added per well the plate shaken overnight at 4°C. The wells were washed three times with the 
binding buffer, then treated for an hour with a 1:1000 dilution of anti His6 mouse monoclonal 
antibody.   A 1:10,000 dilution of goat anti mouse antibody-Horse Radish Peroxide conjugate 
(Abcam) in binding buffer was added to the wells for an hour. The plate was washed, treated with 
TMB and quenched with H2SO4, and the absorbance at 450 nm wavelength measured. From the 
A450 value of each protein concentration, the corresponding blank A450 (with no ligand, same 
amount of protein)  was subtracted. All the A450 values were normalized w.r.t the maximum 
A450 value. They were then fitted by non-linear regression in Graphpad Prism 6.  
5.2.2.6 Non-radioactive kinase assay to evaluate effect of ligands on Akt2 kinase activity  
To evaluate if the cyclic ligand had any effect on the kinase activity of Akt2, we 
performed a preliminary non-radioactive kinase assay with a single concentration of the cyclic 
ligand. The protocol as described in A solution of 400 ng Akt2, 400 ng GST-GSK-3α/β fusion 
protein, 500 mM ATP and 0.5 µL of 90 mM peptide solution or DMSO (control) was made in 
kinase buffer (25 mM trisHCl (pH 7.5), 10 mM MgCl2, 0.01% Triton-X, 1X Roche Phosstop 
phosphatase inhibitor, 1X COMplete protease inhibitor), so that the final concentration of the 
peptide in the reaction mixture was 1.8 mM. The kinase assay protocol as described in Chapter 4, 
subsection 4.2.2.5 was followed.   
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Figure 5.2: Cyclic peptide ligands isolated by screening against target peptide epitope.  
A) Cy(YVYKS-Tz4), B) Cy(VFAKV-Tz4), C) Cy (IRYYS-Tz4), D) Cy(YYTYT-Tz4) 
 
 
 
5.3 Results and discussion 
5.3.1 Verification of on bead cyclization by Edman Peptide Sequencing  
A single bead of tentagel resin from the library was loaded on a cartridge of the Edman 
Sequencer for sequencing. A peptide from library A or C, on Edman sequencing, is expected to 
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generate a particular pattern of signals. During the first sequencing cycle, the amino acid with 
triazole in the side chain should be converted to its PTH derivative. Since the amino acid is still 
attached to the peptide on bead, there should be no peak in cycle 1. From the 2nd cycle onwards, 
the amino acids of the peptide should get sequenced like in a linear peptide. The 7th cycle will 
give the peak corresponding to the triazole side chain derivative. It will cleave as a 
diphenylthiohydantoin derivative. The diphenylthiohydantoin derivative of D-propargylglycine 
amino acid elutes at 25 minutes using the standard amino acid calibration curve. Several random 
beads were picked from library A and sequenced on the Edman. All the random beads from the 
library yielded this pattern, with no peak in cycle 1, then after sequencing 5 amino acids, there is 
a characteristic peak on the 7th cycle. This indicates that the cyclization of peptides on bead by 
CuAAC is a viable and robust and that an on bead CuAAC cyclized library can be readily 
synthesized.  
5.3.2 IR verification of on bead cyclized peptide formation by CuAAC 
reaction 
The MBHA resin, with higher molar capacity than the Tentagel-S-NH2 resin, was used in 
this synthesis, so that any issues of dimerization, which could happen from the on bead 
cyclization, would be more apparent in this case. The cyclized and linear peptides on HPLC 
purification showed one major peak each, which on mass spectral analysis, showed the correct 
mass for the monomeric compound. These pure compounds were analyzed by solid phase IR and 
the spectra compared. While the linear peptide had a distinct peak at ~ 2100cm-1 corresponding to 
azide triple bond rotation, the cyclized peptides did not have this characteristic peak. Thus it was 
demonstrated that the azide on the bead is efficiently cyclized during the click reaction. 
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Figure 5.3: IR spectra of linear peptide L-Pra-VFAKV-L-Az4 and the cyclic peptide 
Cy(VFAKVTz4). 
 
5.3.3 Using on bead cyclic peptide library for ligand discovery  
To eliminate binding to a different region than the phosphorylation site and to prevent 
background binding to the detection antibody, each library was screened against the scrambled 
phospho-epitope, a peptide that does not contain the phosphate and is scrambled in the AGC 
kinase specific motif. In the prescreen the beads binding to the detection antibody and the peptide 
regions other than the hydrophobic motif are detected by the coloration on BCIP treatment. These 
blue beads are separated from the rest of the library that remains colorless. The colorless beads 
  
 
139 
are washed with protein denaturants and then screened with the target phospho-peptide epitope. 
Libraries A and B on screening in this protocol did not yield any hit beads against the target 
phospho-epitope. Only library C yielded four hits. The hits are listed in Table 5.2. 
5.3.4 Determination of best cyclic binder to the target Akt2 C terminal 
fragment 
 The four peptide candidates were tested for their capacity to capture the target peptide in 
a sandwich ELISA platform. Biotinylated capture agents were immobilized on Streptavidin plates 
and titrated with 1 µM of either the His6 tagged target peptide or the scrambled peptide. Binding 
was detected by mouse anti His6 tag antibody. Only peptide Cy(YYTYT-Tz4) showed binding to 
the target peptide and no binding to the scrambled peptide. 
 
Figure 5.4: Selectivity of the cyclic peptide Cy(YYTYT-Tz4) for the target peptide.  
 
 
 
5.3.5 Effect of cyclization on binding specificity  
To determine whether the cyclization of the peptide binder was vital to its binding to the 
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target, the binding of both the linear peptide L-Pra-YYTYT-L-Az4 and the cyclic peptide 
Cy(YYTYT-Tz4) of the peptide ligand with the target were determined. The linear peptide 
exhibited low binding to the target peptide, thus demonstrating that the cyclization of the peptide 
ligand was significant for getting specificity in binding. 
Figure 5.5: The cyclized ligand Cy(YYTYT-Tz4) shows significant binding to the epitope 
compared to its linear version L-Pra-YYTYT-L-Az4. 
 
5.3.6 Effect of ring size on binding 
 To determine whether the ring size of the cyclic peptide binder is an important factor in 
its specificity for the target peptide, the linear peptides L-Pra – YYTYT – L-Az1 and L-Pra – 
YYTYT– L-Az2 were synthesized on resin and subjected to the CuAAC reaction overnight. The 
peptide L-Pra – YYTYT – L-Az1 failed to cyclize on bead. The peptide L-Pra –YYTYT– L-Az2 
could be cyclized. This cyclic peptide of smaller ring size did not exhibit significant binding to 
the target peptide, and thus it could be demonstrated that the ring size of the cyclic peptide is an 
important criteria for binding the target peptide. 
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Figure 5.6: Ring size affects cyclization efficiency. 
L-Pra – YYTYT– L-Az2 cyclizes on bead as the major product while L-Pra – YYTYT– L-Az1 
does not cyclize efficiently on bead 
 
 
Figure 5.7: Effect of ring size on epitope selectivity. 
Cy(YYTYT-Tz4) is a better binder than Cy(YYTYT-Tz2) 
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5.3.7 Characterization of the cyclic ligand Cy(YYTYT-Tz4)  
To determine the affinity of the cyclic monoligand for full length Akt2 protein, the ligand 
was titrated against immobilized protein. The ligand acts as a detection agent and has a low 
nanomolar (124 nM) binding affinity compared to the low micromolar affinity (3.6 µM) of the 
linear monoligand previously developed against Akt. Thus there is a ~ 30 fold improvement in 
the binding affinity using a cyclic instead of linear peptide monoligand for Akt2. It will be 
interesting to see if the same improvement can be attained in the biligand stage using a cyclic 
peptide as the 2 °arm. 
We demonstrate the selectivity of the cyclic monoligand for Akt2 protein by comparing 
the binding of the ligand to the proteins Akt1, Akt2 and Akt3. As the proteins are highly 
homologous, even in the targeted C terminal region, it is not surprising that binding to all the 
three proteins is observed to some extent. However there is a distinct preference for Akt2.  
Figure 5.8: Determination of binding affinity of cyclic ligand Cy(YYTYT-Tz4) for Akt2 
protein 
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Figure 5.9: Cy(YYTYT-Tz4) is selective for the Akt2 protein over the Akt1 and Akt3 
proteins. 
 
5.3.8 Effect of cyclic monoligand on Akt2 kinase activity  
To evaluate if the cyclic ligand has any effect on the kinase activity of the Akt2 protein, 
we performed the non-radioactive kinase assay described in Chapter 4. Briefly, the protein is 
treated with the ligand, ATP and an enzyme substrate, in this case, GST-GSK-3α/β fusion 
protein. The reaction mixture is analyzed using western blot to detect the amount of substrate 
phosphorylated. Under normal conditions (as in the DMSO control) the GST-GSK-3α/β fusion 
protein will be phosphorylated by Akt2. If, however, the ligand acts as an inhibitor, it will 
decrease the formation of phospho-Ser21/9- GST-GSK-3α/β fusion protein. The cyclic 
monoligand, Cy (YYTYT-Tz4) inhibits the phosphorylation of the substrate. As this was a 
preliminary experiment, we used a high concentration (2mM) of the cyclic ligand. Further 
verification with lower concentrations of the cyclic peptide is required. 
Figure 5.10: Cyclic ligand Cy(YYTYT-Tz4) inhibits Akt kinase activity. 
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5.3.9 Optimization of monoligand anchor 
To introduce an azide handle on the monoligand to screen against an OBOC library 
containing Alkyne handle, 6- azido hexanoic acid is coupled to N terminal of cyclic peptide to 
develop the monoligand anchor. The protein is incubated with the monoligand anchor and 
screened against library D. There was very little background binding to the antibody in the 
preclear screen, and in the actual screen no hits were obtained. During the purification of the 
monoligand anchor peptide on the HPLC using a standard gradient, we observed a significant 
difference in the elution time. While the monoligand eluted at 50 minutes, the monoligand anchor 
eluted at 65 minutes using the same gradient. The significant change in elution times on addition 
of a single amino acid to a peptide probably implies that this addition is altering the nature of the 
peptide. It is possible that the click handle in the monoligand anchor is not available for reaction 
with the on bead alkyne because the azide containing side chain is binding to the cyclic part of the 
peptide. It is observed that use of an alternative version of the monoligand anchor with a glycine 
and azidoalanine (instead of the 6-azidohexanoic acid) decreases the gap in HPLC elution, eluting 
close to the monoligand. This is chosen as the monoligand anchor candidate for the biligand 
screen.   
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Figure 5.11: Monoligand anchor candidate peptides developed for biligand screen. 
The length of the azide side chain is same for both  
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Figure 5.12: Comparison of HPLC traces to determine best monoligand anchor candidate. 
Monoligand anchor A is significantly different in character from the monoligand Cy(YYTYT-
Tz4) while monoligand anchor B is similar in character. 
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5.4 Conclusion 
In this chapter we have described the development of a Cu catalyzed cyclic library and 
demonstrated its use in OBOC screening. Although on bead cyclization of some specific peptide 
sequences through CuAAC have been demonstrated, we are not aware of use of CuAAC cyclized 
comprehensive libraries in OBOC screening. The libraries were developed with a specific aim in 
mind, isolating monoligands with high affinity to render the epitope targeting strategy more 
effective. This aim has been fulfilled. We were able to demonstrate the binding of the PCC agent 
to the epitope in the monoligand stage itself. The cyclic monoligand has a significantly higher 
binding affinity for the protein compared to the linear monoligand developed using the peptide 
epitope. It is also selective enough to distinguish between various Akt isoforms. Finally, we have 
preliminary data that the cyclic ligand is an inhibitor of the kinase activity of the Akt2 enzyme. 
We have optimized the monoligand anchor to be used in developing the biligand. The biligand 
will be bicyclic, and hopefully, will have affinity and specificity similar to a monoclonal 
antibody. 
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